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1. Introduction 
1.1 Chronic Kidney disease  
 
Chronic kidney disease (CKD) is a gradual progressive loss of kidney function leading 
to end-stage renal failure which requires kidney replacement for survival. The 
prevalence of this disease is increasing worldwide. For example, CKD affects about 
11.6% of the adult population in the United States (US) and its rising prevalence also 
appears in Europe and in other countries (Coresh et al., 2003). The guidelines published 
in the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney 
Foundation describe the definition of CKD and classify stages of kidney disease 
progression (MacGregor et al., 2006; National Kidney Foundation, 2002). CKD is 
defined as a decline in glomerular filtration rate (GFR) and kidney damage with the 
increase of proteinuria or urinary albumin or protein to creatinine ratio or albuminuria to 
creatinine ratio. K/DOQI defines CKD as GFR <60 ml/min/1.73 m2 for ≥ 3 months, with 
or without the presence of kidney damage. Kidney Disease Improving Global Outcomes 
(KDIGO) provides the guideline for the definition and classification of CKD and its 
management (Levey et al., 2005). It is to improve the care and outcomes of kidney 
disease patients worldwide through promoting coordination, collaboration and 
intergration of initiatives to develop and implement clinical practice guidelines. CKD in 
KDIGO guideline has been classified into 5 stages based for K/DOQI definition and 
classification (Table 1 and 2). The causes of CKD are mainly diabetic nephropathy (type 
1 or 2 diabetes mellitus) and hypertension. Other conditions including 
glomerulonephritis, nephrosclerosis, and hereditary renal disease can also affect kidneys.  
 
 
 
Table 1. Definition of chronic kidney disease. Taken from (Levey et al., 2005) 
 
Kidney damage for ≥ 3 months, as defined by structural or functional abnormalities of the kidney, with or 
without decreased GFR, that can lead to decreased GFR, manifest by either: 
- Pathologic abnormalities; or 
- Markers of kidney damage, including abnormalities in the composition of the blood or urine, or 
abnormalities in imaging tests 
GFR < 60 mL/min/1.73 m2 for ≥ 3 months, with or without kidney damage 
GFR, glomerular filtration rate 
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Table 2. Definition and classification of chronic kidney disease. Kidney Disease Improving Global 
Outcomes (KDIGO). Taken from (Levey et al., 2005) 
Stage Description GFR 
ml/min/1.73m2 
Related terms Classification by 
treatment 
1 
 
2 
 
3 
 
4 
 
 
5 
Kidney damage with 
normal or ↑ GFR  
Kidney damage  
with mild ↓ GFR 
Moderate ↓ GFR  
 
Severe ↓ GFR 
 
 
Kidney failure 
≥ 90 
 
60 – 89 
 
30 – 59 
 
15 – 29 
 
 
< 15 (or 
dialysis) 
Albuminuria, proteinuria,  
hematuria 
Albuminuria, proteinuria, 
hematuria 
Chronic renal insufficiency, 
early renal insufficiency 
Chronic renal insufficiency, 
late renal insufficiency, pre-
ESRD 
Renal failure, ureamia, end-
stage, renal disease 
 
 
 
 
T if kidney 
transplant, recipient 
    D if dialysis 
(hemodialysis, 
peritoneal dialysis) 
“T” for all kidney transplant recipients, at any level (CKD stages 1 to 5) and “D” for dialysis, for CDK 
stage 5 patients treated by dialysis. GFR, glomerular filtration rate; ESRD, end-stage renal disease. 
 
1.1.1 Development of glomerulosclerosis 
 
Progressive renal disease is generally characterized by glomerulosclerosis, interstitial 
leukocyte infiltration, tubular atrophy, and interstitial fibrosis (Remuzzi and Bertani, 
1998). Both the glomerulus and the tubulointerstitium are involved in the 
pathophysiologic changes contributing to progression of the disease. Glomerulosclerosis 
is a major cause of chronic and end-stage renal disease (ESRD). A normal structure of 
glomerulus consists of endocapillary compartment containing mesangial cells and 
capillary and extracapillary compartment containing podocytes and Bowman´s capsule 
(Abrahamson, 1987; Kriz et al., 1995). The glomerular tuft is composed of three types of 
cells: endothelial cells at the inside of the capillary, podocytes on the outside of the 
capillary, and mesangial cells filling the space between the capillary loops (Leeuwis et 
al., 2010). Podocyte loss is a common feature in many kidney diseases including diabetic 
(Pagtalunan et al., 1997; Steffes et al., 2001; Stieger et al., 2011) and non-diabetic renal 
diseases, e.g. focal segmental glomerulosclerosis (FSGS) or membranous 
glomerulopathy or amyloid nephropathy (Kriz, 1996; Shankland, 2006). Podocytes are 
terminally differentiated glomerular visceral epithelial cells that are specialized to their 
location, architecture, and cellular character. During nephrogenesis, podocytes derive 
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from mesenchymal cells and develop as a distinct cell layer at the stage of the so-called 
S-shaped bodies. At the stage of capillary loop, podocytes establish their characteristic 
complex cell architecture, including the formation of foot processes and a slit membrane 
(Figure 1). The cell body of podocytes lies in the urinary space. From these cell bodies 
arise long primary processes that extend further to secondary foot processes by attaching 
to the underlying glomerular basement membrane (GBM) via integrins and 
dystroglycans. The foot processes interdigitate with foot processes of neighboring 
podocytes, leaving in between the filtration slit which is bridged by the slit diaphragm. 
Finally, the large structure of the cells hangs in the urinary space of capillary wall 
(Mundel and Kriz, 1995; Smoyer and Mundel, 1998). Ultimately, differentiated adult 
podocytes may undergo mitosis (nuclear division), but are unable to undergo cytokinesis 
(cell division) resulting in bi-(multi)-nucleated podocytes. As a consequence, injured 
podocytes are incapable to proliferate or cannot be easily replaced, whereas other renal 
parenchymal cells, e.g. mesangial cells are able to regenerate. Therefore, podocyte 
damage involves the problem of insufficient podocyte repair resulting in secondary 
scarring processes leading to progressive glomerulosclerosis (Kriz, 1996; Pavenstadt et 
al., 2003; Wiggins, 2007). 
The development and progression of glomerulosclerosis is described in a model shown 
in Figure 2 (Kriz, 1996; Kriz et al., 1998). When an area of denuded capillary comes into 
contact with parietal cells of Bowman´s capsule, the latter are apparently triggered to 
attach to the capillary basement membrane. A “beach head” of parietal epithelium is 
thereby established on the tuft which represents the beginning of a synechia or tuft 
adhesion for the further development of segmental sclerosis. At the site of the 
attachment of parietal cells to the capillary, a gap in the parietal epithelium comes into 
existence, permitting filtration/exudation towards the cortical interstitium (Figure 2b). 
The parietal epithelium spreads to neighboring capillary loops. Capillaries inside the 
adhesion either collapse or are occluded by hyalinosis (shown in a dark grey pattern). 
Podocytes which are located at the flanks of the adhesion will degenerate by several 
mechanisms. The parietal epithelium may either appose those podocytes (arrowhead) or 
attach directly to the GBM at the flanks of the adhesion. Fluid leakage from perfused 
capillaries inside the adhesion has created a paraglomerular space (shown in yellow) that 
contains the sclerotic tuft remnants (that is, collapsed or hyalinized GBM formations). 
Towards the cortical interstitium, the paraglomerular space has become separated by a 
layer of sheet-like fibroblast processes (shown in green) (Figure 2c). 
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Figure 1. Development of nephron. During the induction of the metanephric mesenchyme, cells 
condense around the tips of the branching ureteric bud, and convert to an epithelial cell type (MET, 
mesenchymal-to-epithelial transition). These early epithelial cells form a spherical cyst called the renal 
vesicle (B), the renal vesicle aggregates to the comma-shaped (C), and then the S-shaped bodies (D). At 
this stage, the proximal end of the S-shaped body becomes invaded by blood vessel, differentiates into 
podocytes and parietal epithelial cells, and then generates the glomerular tuft (E, F).  Simultaneously, the 
middle and the distal segments of the S-shaped body that had remained in contact with the ureteric bud 
epithelium fuse to form a single, continuous epithelial tube and begin to express proteins that are 
characteristic of tubular epithelia (Romagnani, 2009). 
 
The sclerotic process has reached a further lobule via the vascular pole. A small "intact" 
tuft remnant protrudes into the urinary space still covered by the parietal epithelium. The 
sclerotic tuft remnants are located outside the parietal epithelium in the paraglomerular 
space that is separated from the cortical interstitium by a complete layer of cortical 
fibroblasts. Even in late stages of injury, perfused capillaries are regularly found within 
the sclerotic regions, probably accounting for the further expansion of the 
paraglomerular space that may extend to the proximal tubule. In later stages, fibroblasts 
will invade the sclerotic area, resulting in fibrous organization (Figure 2d) (Kriz et al., 
1998).  
   7 
 
Figure 2. Schematic to show the progression of segmental to global glomerulosclerosis. (a) Normal 
glomerulus with vascular and urinary poles. Smooth muscle cells, extra glomerular mesangial cells, and 
mesangial cells are hatched; podocytes are shown in blue-green, parietal epithelial cells in red. The GBM 
is shown in black, the parietal basement membrane in yellow, tubular epithelia are shown in white (b) A 
denuded capillary is attached to Bowman’s capsule. Parietal cells attach to the naked GBM. (c) The 
adhesion has spread to neighboring capillaries resulting in either the collapse or in hyalinosis (shown in a 
dark grey pattern). The parietal epithelium may either appose the degenerated podocytes (arrowhead) or 
attach directly to the GBM at the flanks of the adhesion. Fluid leakage from perfused capillaries inside the 
adhesion has created a paraglomerular space (shown in yellow) that contains the sclerotic tuft remnants 
(that is, collapsed or hyalinized GBM formations). Towards the cortical interstitium this paraglomerular 
space has become separated by a layer of sheet-like fibroblast processes (shown in green). (d) The 
sclerotic process jumps, via the vascular pole, to a neighbouring lobule. Even in late stages of injury 
perfused capillaries are regularly found within the sclerotic regions. In later stages, In the sclerotic area 
invaded by cortical fibroblats, fibrosis will appear. Taken from (Kriz et al., 1998). 
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Figure 3. The spectrum of podocyte diseases.  Glomerular diseases with podocyte dysfunction are 
developed by genetic and/or environmental factors. Depending on the stage of glomerular development 
and associated environmental factors, podocyte dysfunction, injury, or loss can result in a broad spectrum 
of clinical syndromes. All these conditions account for 90% of end-stage kidney disease. DMS, Diffuse 
mesangial sclerosis; CNSF, congenital nephrotic syndrome of the Finnish type; Alport +, Alport syndrome 
and variants; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; Collapsing GN, 
collapsing glomerulonephropathy; Imm/Infl GN, immune and inflammatory glomerulophropathies; HTN, 
hypertensive nephropathy; Diab GN, diabetic glomerulonephropathy; Aging, age-associated 
glomerulonephropathy. Taken from (Wiggins, 2007). 
 
1.1.2 Glomerulosclerosis-associated chronic kidney diseases 
 
Understanding the pathomechanisms of glomerular diseases requires profound 
knowledge of podocyte biology. Glomerular injury results in a sequence of events 
including podocyte injury, dysfunction, and loss. These pathologic events are consistent 
with an increase of proteinuria and a global glomerulosclerosis. Genetic as well as 
environmental factors also control the development and maintainance of normal 
glomerular structure and function by targeting podocytes. The most common forms of 
glomerular diseases occur in patients with diabetes and focal segmental 
glomerulosclerosis. Another form is chronic glomerulonephritis caused by systemic 
disorders (Systemic lupus erythematosus [SLE], Goodpasture´s syndrome, and IgA 
nephropathy) or post-infection by bacteria or viruses. There are also hereditary diseases, 
e.g. Alport nephropathy, minimal change disease (MCD), and membranous nephropathy 
(MN) (Figure 3) (Leeuwis et al., 2010; Shankland, 2006; Wiggins, 2007).  
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1.2 Contributing factors of disease progression in CKD 
 
Progressive renal disease involves glomerulosclerosis and fibrosis in response to renal 
injury which is caused by various factors of age, immunological reactions, 
hypoxia/ischemia, endo- and exogenous products, metabolic syndrome, and genetic 
defects (Kronenberg, 2009). In the processes of inflammation and fibrosis, both 
glomerular and tubulointerstitial compartments including renal parenchymal cells, 
infiltrating and resident immune cells, and fibroblasts contribute to disease progression. 
These cells are major sources of many soluble mediators such as cytokines/chemokines, 
growth factors, and lipid mediators, which mediate proinflammatory and profibrotic 
responses (Schlondorff, 2008).  
Renal inflammation is not only present in kidney diseases such as glomerulonephritis, 
and renal vasculitis but also in other types of kidney diseases such as diabetic 
glomerulosclerosis, renal atherosclerosis, Alport nephropathy, and polycystic kidney 
disease. Several factors including infectious, toxic, metabolic, ischemic, traumatic, and 
genetic factors may directly or indirectly trigger tissue injury resulting in renal 
inflammation (Figure 4) (Anders, 2010).  
 
Figure 4. Scheme of factors triggering the disease progression. The pathogen- or non-pathogen factors 
activate sensors expressed by immune and renal cells to produce a variety of proinflammatory and 
profibrotic mediators aggravating the disease. Taken from (Anders, 2010). 
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1.2.1 Leukocyte infiltration in CKD 
 
Monocyte/Macrophage-driven renal inflammation and parenchymal cell loss  
 
Studies have shown that infiltrating immune cells such as lymphocytes, neutrophils, 
denritic cells, and macrophages are associated with the progression of kidney disease 
(Kluth et al., 2004; Ricardo et al., 2008). Circulating monocytes or tissue macrophages 
are well-known to have a pivotal role in pathogenesis of many kidney diseases. For 
example, increased number of macrophages has been found in several renal disease 
models including nephrotoxic or anti-GBM glomerulonephritis (Duffield et al., 2005; 
Ikezumi et al., 2003), IgG or lupus nephritis (Tesch et al., 1999), renal allograft injury 
(Jose et al., 2003), ischemia reperfusion injury (IRI) (Bonventre and Zuk, 2004), 
unilateral ureteric obstruction (UUO) (Kipari et al., 2006), adriamycin nephrosis (Wang 
et al., 2008), and diabetic nephropathy (DN) (Chow et al., 2004a; Chow et al., 2004b; 
Ninichuk et al., 2007). These cells contribute to aggravation of renal injury and renal 
failure by releasing a variety of proinflammatory cytokines, chemokines, nitric oxide 
(NO), and reactive oxygen species (ROS) that cause inflammation in kidney.  
Several interventional studies demonstrated that inhibition of monocyte/macrophage 
recruitment and their activation reduced renal inflammation and fibrosis. Other 
evidences using rodent models also provided that depletion (ablation) of 
monocyte/macrophage attenuated kidney diseases. For example, the effects of liposomal 
clodronate on renal inflammation and fibrosis have been investigated using several 
kidney disease models such as IRI and UUO (Jo et al., 2006; Kitamoto et al., 2009). 
Using CD11b-DTR (Diphtheria toxin receptor) transgenic mice, circulating monocytes 
and renal macrophages but not Kupffer cells or alveolar macrophages can be depleted 
and their effect on renal protection has been studied (Duffield et al., 2005; Qi et al., 
2008). Inhibition of colony stimulating factor-1 (CSF-1) can modulate 
monocyte/macrophage accumulation and proliferation. Furthermore, it also decreases 
tubular cell apoptosis (Lenda et al., 2003; Ma et al., 2009). Chemokine or chemokine 
receptor antagonists can also be used to block the recruitment of activated 
monocytes/macrophages. The role of proinflammatory chemokine C-C motif ligand 
2/monocyte chemoattractant protein-1 (CCL2/MCP-1) as well as the chemokine C-C 
motif receptor 2 (CCR2) has been studied in various renal disease models. CCL2/MCP-1 
inhibition reduces intra-renal macrophage infiltration and improves lupus nephritis in 
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MRL/lpr mice (Kulkarni et al., 2009; Kulkarni et al., 2007) and diabetic nephropathy in 
db/db mice (Ninichuk et al., 2008). CCR2 deficiency or blockade also reduces monocyte 
infiltrate and renal injury in IRI (Li et al., 2008) or DN (Kang et al., 2010; Sayyed et al., 
2011). CCR5 deficiency also improves renal allograft injury by increasing a number of 
alternatively activated macrophages (Dehmel et al., 2010). 
Several evidences indicate multiple mediators produced by macrophages induce 
apoptosis of renal parenchymal cells including mesangial cells, podocytes, and tubular 
cells. Duffield et al. demonstrated that activated macrophages regulate mesangial cell 
number via apoptosis. M1 macrophages primed with interferon-γ (IFN-γ), 
lipopolysaccharides (LPS) or tumor necrosis factor-α (TNF-α) induced apoptosis and 
suppressed mitosis of mesangial cells (Duffield et al., 2000). Podocyte loss is a sign for 
kidney disease progression. Leukocyte-mediated inflammation may be a major factor of 
the podocyte apoptosis. In vitro studies show that TNF-α released from M1 macrophages 
causes down-regulation of nephrin and podocin expression in podocytes (Ikezumi et al., 
2008). In addition, macrophages are associated with apoptosis of other types of 
parenchymal cells such as tubular cells using IRI and UUO models. Macrophage 
accumulation can be blocked using CD11b-DTR transgenic mice or the macrophage 
colony-stimulating factor receptor (c-fms) inhibitors. The approaches can also inhibit the 
recruitment of other immune cells, e.g. CD4 Th1 cells, which have a potential to activate 
macrophages, and lead to the reduction of proinflammatory cytokine such as TNF-α and 
matrix metalloproteinase-12 (MMP-12), and tubular cell apoptosis in the obstructed 
kidney (Duffield et al., 2005; Ma et al., 2009; Qi et al., 2008). Another study reported 
that direct inhibition of the macrophage products, e.g. inducible isoform nitric oxide 
synthase (iNOS) also reduced tubular cell apoptosis (Kipari et al., 2006). Finally, ex vivo 
programmed M1 macrophage induced more renal injury, whereas M2 macrophage 
ameliorated chronic inflammatory renal disease in mouse model (Wang et al., 2007).  
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Figure 5. The phenotype switch of macrophages by immune cell-produced cytokines. Classically 
activated macrophages (M1) arise in response to interferon-γ (IFN-γ), which are produced by T helper 1 
(Th1) cells or CD8+ T cells or by natural killer (NK) cells, and tumor necrosis factor-α (TNF-α), which is 
produced by antigen-presenting cells (APCs). Wound-healing (alternatively activated) macrophages (M2a) 
arise in response to interleukin-4 (IL-4), which is produced by Th2 cells or by granulocytes. Anti-
inflammatory macrophages (M2c) are generated in response to various stimuli including apoptotic cells, 
glucocorticoids, or IL-10. Taken from (Mosser and Edwards, 2008). 
 
 
Macrophage phenotypes 
 
Circulating monocytes that originate from bone-marrow myeloid progenitor cells can 
differentiate into renal macrophages and dendritic cells (DCs). Macrophages are 
characteristically and functionally classified into two distinct subsets that are described 
as classically activated (M1) and alternatively activated (M2) macrophages (Figure 5) 
(Mantovani et al., 2004; Mosser and Edwards, 2008).  IFN-γ which is produced by 
CD4+ T helper 1 (Th1) cells, CD8+ cytotoxic T cells, and natural killer (NK) cells, can 
activate macrophages either alone or the combination with LPS, TNF-α, and other 
microbial products. The activated macrophages (M1) can be characterized by enhanced 
microbicidal capacity and high level of proinflammatory cytokines (e.g. interleukin-12 
[IL-12] and IL-23) (Trinchieri, 2003), major histocompatibility complex classs II 
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(MHCII), toxic nitric oxide and reactive oxygen intermediates (ROI) (Mantovani et al., 
2004). In contrast to the M1 polarized cells, which have a proinflammatory function, the 
alternative M2 macrophages are known as antiinflammatory cells. They generally 
deactivate macrophages via Th2 cell response resulting in tissue remodeling and repair, 
resistance to parasites, immunoregulation and tumour induction (Gordon, 2003; Gordon 
and Martinez, 2010). M2 cells are divided into three groups. M2a cells arise in response 
to IL-4 or IL-13, M2b macrophages are exposed to immunocomplexes and activated 
with LPS, and M2c macrophages are activated by antiinflammatory molecules such as 
IL-10, transforming growth factor-β (TGF-β), and glucocorticoids. IL-4 or IL-13 
produced by Th2 cells or granulocytes induces the M2a phenotype, which expresses low 
levels of proinflammatory cytokines and high levels of antiinflammatory cytokines. The 
synthesis of IL-1 receptor antagonist and the decoy IL-1 receptor (IL-1RII) is increased 
and mannose and scavenger receptors are also highly expressed. M2a macrophages 
activated by IL-4 strongly produce chitinase and chitinase-like molecules including Ym-
1 (CHI3L3) and Fizz-1 (RELMα). These alternatively activated macrophages inhibit NO 
synthesis (NOS activity) and enhance to produce polyamines by increasing arginase-1 
(Arg-1). M2b macrophages primed with IgG immune complexes are activated by LPS 
produce high levels of IL-10 and low levels of IL-12. These cells have a more 
antiinflammatory phenotype, although they also produce MHCII and some 
proinflammatory cytokines such as IL-1, IL-6, and TNF-α. M2c macrophages termed as 
deactivated macrophages are induced by IL-10, TGF-β, and glucocorticoids. They 
produce high levels of IL-10 and adopt an immunosuppressive role contributing to the 
resolution of inflammation, tissue repair, and matrix remodeling (Gordon and Martinez, 
2010; Mantovani et al., 2004; Varin and Gordon, 2009a).  
An additional macrophage type, tumor-associated macrophages (TAMs) originate from 
blood monocytes and mostly occurr at tumor sites. Monocytes recruited by tumor-
derived factors promote differentiation of monocytes to mature macrophages (M2-like 
macrophage) and simultaneously block the differentiation of DCs. TAMs can release a 
vast diversity of growth factors, proteolytic enzymes, cytokines, and inflammatory 
mediators. Main functions of TAMs are tumor progression and metastasis and show 
mostly similar characteristics of M2 polarized macrophage by expressing abundant 
immunosuppressive cytokines such as IL-10 and TGF-β. Moreover, TAMs are poor 
producers of NO, ROI, and proinflammatory cytokines contrast to M1 macrophages 
(Coffelt et al., 2009; Sica et al., 2008; Solinas et al., 2009). These cells can sometimes be 
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termed as myeloid-derived suppressor cells (MDSCs) that expand during cancer, 
inflammation and infection. Under these pathological conditions, some myeloid 
precursor cells, which fail to develop functionally competent antigen-presenting cells, 
differentiate into MDSCs and produce either Arg-1 or iNOS. The phenotypes of MDSCs 
have been identified as CD11b+Gr1+ in mice, and as LIN-HLA-DR-CD33+ or 
CD11b+CD14-CD33+ in human. Although most of phenotypes are shared with TAMs, 
MDSCs can be distinguished from TAMs due to several criteria, for example, high 
expression of Gr-1, low expression of F4/80, and the expression of both Arg-1 and iNOS 
(Almand et al., 2001; Gabrilovich and Nagaraj, 2009; Ribechini et al., 2010).    
Fibrocytes are another type of monocyte lineage, which share the phenotypic 
characteristics of leukocytes as well as mesenchymal cells. Generally, these cells are 
characterized by a distinct cell surface phenotype, for example, the hematopoietic stem 
cell/progenitor marker CD34, the pan-leukocyte marker CD45, monocyte lineage 
markers (CD11b, CD13), and fibroblast products (collagen I, fibronectin, and vimentin) 
(Bellini and Mattoli, 2007; Bucala et al., 1994). Many recent studies indicate that 
fibrocytes contribute to the renal fibrosis in progressive kidney diseases (Niedermeier et 
al., 2009; Wada et al., 2007). 
  
1.2.2 Role of tumor necrosis factor-α in CKD 
 
CKD is accompanied by progressive loss of parenchymal cells such as podocytes and 
tubular epithelia. In Alport nephropathy, the digestion of GBM leads to GBM damage 
and podocyte loss. The factors which accelerate loss of renal cells may have a role in 
cellular apoptosis. TNF-α is a pleiotropic cytokine that regulates several cellular 
responses including proinflammatory cytokine production, cell survival, cell 
proliferation, and paradoxically, cell death (Varfolomeev and Ashkenazi, 2004). A 
variety of cell types such as macrophages, lymphocytes, natural killer cells, and 
epithelial cells secrete TNF-α. It is primarily expressed as a type II transmembrane 
protein arranged in stable homotrimers. From its transmembrane precursor form, the 
soluble homotrimeric cytokine (sTNF) is released via proteolytic cleavage by the 
metalloprotease TNF-alpha converting enzyme (TACE). Three classes of TNFs have 
been identified: TNF-α, LT-α (lymphotoxin-α also known as TNF-β), and LT-β (Ware, 
2005). Soluble TNF-α is a homotrimer of 17 kDa cleaved monomers and transmembrane 
TNF-α is 26 kDa uncleaved monomers (Tang et al., 1996; Wajant et al., 2003). 
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Biological functions of TNF-α are initiated by interacting with their membranous 
receptors: TNF receptor 1 (TNF-R1) and TNF–R2. TNF-R superfamily members are 
composed of cystein-rich extracellular domains that bind their respective ligands, and 
intracellular interaction motifs such as the death domain (DD) and the TNF-receptor 
associated factor (TRAF)-binding domain. DD containing receptors such as TNF-R1, 
FAS, and DR3 activate caspase cascade and apoptosis induction by recruiting 
intracellular adaptor molecules such as FAS-associated death domain (FADD), TNFR-
associated death domain (TRADD), and receptor interacting protein (RIP). TNF-α can 
also activate cell survival and death via nuclear factor-kappa B (NF-κB) pathway by 
binding to either TNF-R1 or TNF-R2. These receptors recruit TRAF family molecules to 
activate both NF-κB inducing kinase (NIK) and mitogen-activated protein (MAP) kinase 
(MAPK) kinase-1 (MEKK1), which converge on the IκB kinase (IKK) signalosome 
complex. This signaling cascade ultimately leads to NF-κB nuclear translocation (Figure 
6) (Hehlgans and Pfeffer, 2005; Rahman and McFadden, 2006; Wajant et al., 2003). 
Pharmacologically, TNF-α signaling can be blocked by biologic agents targeting soluble 
or transmembranous TNF-α. Anti-TNF agents have been successfully applied to the 
treatment of patients with a number of immune-mediated inflammatory disorders such as 
rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease 
(IBD), and psoriasis with or without complicating arthritis (Feldmann and Maini, 2003). 
Commercially available blockers of TNF-α activity for patient use are, for example, the 
TNF-specific monoclonal antibodies, infliximab (Remicade®), adalimumab (Humira®), 
and golimumab (Simponi®). In addition, the PEGylated Fab´antibody fragment 
certolizumab pegol (Cimzia®) has also been approved for clinical use. Etanercept 
(Enbrel®) is another biological drug. It is a fusion protein of TNFR2 with the Fc portion 
of human IgG and it is specific for a soluble TNF (Figure 7). Etanercept is composed of 
the extracellular region of the two human TNFR2 (p75 TNF rceptor) linked to the Fc 
region (CH2 and CH3 domains) of human IgG1. It consists of 934 amino acids with an 
approximate molecular weight of 150 kDa. Etanercept inhibits binding both TNF-α and 
LTα to TNF receptors on the cell surface (Horiuchi et al., 2010; Taylor, 2010). 
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Figure 6. TNF-α-mediated death and survival pathways. TNF-α-mediated death and survival pathways 
are activated following interaction with the TNFRs. The apoptotic pathway is activated through TNFR1 by 
forming the DISC, which activates caspases. Activated caspase-8 or −10 then activate proapoptotic Bcl-2 
family members, which leads to cell death by releasing cytochrome c from mitochondria and loss of 
mitochondrial membrane potential (MMP). The NF-κB-mediated survival pathway is activated by both 
TNFR1 and TNFR2. Association of TRAFs with these receptors activate signaling proteins like NIK (NF-
κB inhibitor kinase) and MEKK1 (MAPK kinase 1), which activate the inhibitor of NF-κB (IkB) kinase 
(IKK) signalosome complex. IKK phosphorylates IkB, resulting in the degradation of the inhibitor. The 
free NF-κB than translocates to nucleus to induce the expression of inflammatory or antiapoptotic genes. 
Taken from (Rahman and McFadden, 2006) 
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Figure 7. TNF-α-specific antibodies. Certolizumab pegol is a PEGylated Fab´antibody fragment. 
Infliximab is a mouse-human chimeric monoclonal anti-TNF-α antibody of IgG1 isotype. Adalimumab 
and golimumab are fully human IgG1 monoclonal antibodies. Etanercept is a fusion protein of the 
extracellular domain of TNFR2 and the Fc region of human IgG1 and binds TNF-α, LTα3 and LTα2B1. 
Taken from (Hoshino et al., 1999; Taylor, 2010). 
 
 
1.2.3 Pattern recognition receptors and innate immunity 
 
Immune response is a crucial process to defend against invading pathogens and it affects 
disease pathology. The mammalian immune system consists of two distinct arms, innate 
and adaptive immunity. Effective cooperation of these two connected systems is 
essential. The innate immune system is an evolutionarily conserved system to recognize 
a unique molecular structure on the surface of different pathogens, such as bacteria, 
viruses, and parasites, using receptors of host cells to eliminate invaders. Innate immune 
cells express a number of pattern-recognition receptors (PRRs) that recognize microbial 
molecules known as pathogen-associated molecular patterns (PAMPs) (Janeway and 
Medzhitov, 2002; Medzhitov and Janeway, 2000). The different classes of PRR families 
include transmembrane proteins such as toll-like receptors (TLRs), C-type lectin 
receptors (CLRs), as well as cytoplasmic proteins such as retinoic acid-inducible gene 
(RIG)-I-like receptors (RLRs) and nucleotide-binding oligomerization domain 
containing (NOD)-like receptors (NLRs) (Table 3) (Akira et al., 2006; Hoffmann, 2003; 
Kumar et al., 2009; Medzhitov, 2007). 
TLRs are evolutionally conserved from insects to mammals. 10 and 12 members of the 
TLR family have so far been identified in humans and in mice, respectively (Akira and 
   18 
Takeda, 2004; Beutler, 2004; Hoffmann, 2003; Janeway and Medzhitov, 2002). TLR1-9 
are conserved in both species. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are 
expressed on the cell surface and recognize mainly microbial components such as lipids, 
lopoproteins and proteins. TLR3, TLR7, TLR8, and TLR9 are present exclusively in 
intracellular compartments such as endoplasmic reticulum (ER), endosomes, lysosomes 
and endolysosomes and they recognize microbial nucleic acids (Kawai and Akira, 2009).  
TLRs are type I integral membrane glycoproteins and possess three major domains. The 
extracellular N-terminal domain, which consists of approximately 16-28 leucin-rich-
repeat (LRR) motifs. Each LRR consists of 20-30 amino acids with conserved motif 
“LxxLxLxxN”. Furthermore, there is a transmembrane domain and a cytoplasmic 
signaling domain termed the Toll/IL-1R homology (TIR) domain (Akira and Takeda, 
2004).  
 
TLR 4 
 
TLR4 is activated by LPS, the outer membranes glycolipid of Gram-negative bacteria, 
which promotes innate immune responses (Hoshino et al., 1999; Poltorak et al., 1998). 
TLR4 is located with MD-2 on the cell surface and the TLR4-MD2 heterodimer is 
recognized by LPS and initiates signal transduction by intracellular adaptor molecules 
(Park et al., 2009; Shimazu et al., 1999). LPS also binds additional proteins such as LPS 
binding protein (LBP) and CD14, a glycosylphosphatidylinositol (GPI)-anchored 
molecule expressed in monocytes/macrophages. LPS-LBP complex is recognized by 
CD14 and transferred to the TLR4-MD-2 complex. TLR4 activates two cytoplasmic 
signal pathways: a MyD88-dependent and a TRIF-dependent pathway (Jiang et al., 
2005; Wright et al., 1990). 
TLR4 is also involved in the recognition of viral envelope proteins and endogenous 
ligands, such as heat shock proteins (Hsp60 and Hsp70), the extra domain A of 
fibronectins, oligosaccharides of hyaluronic acid, heparin sulfate and fibrinogen, 
although these endogenous ligands require high concentrations to activate TLR4 (Gao 
and Tsan, 2003; Ohashi et al., 2000).   
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Table 3. PRRs and their ligands. Taken from (Takeuchi and Akira, 2010)  
PRRs  Localization Ligand Origin of the ligand 
TLR    
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein Bacteria, viruses, parasites, self 
TLR3 Endolysosome dsRNA Virus 
TLR4 Plasma membrane LPS Bacteria, viruses, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR7 
(humanTLR8) Endolysosome ssRNA Virus, bacteria, self 
TLR9 Endolysosome CpG-DNA Virus, bacteria, protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
RLR    
RIG-I Cytoplasm Short dsRNA, 5´triphosphate 
dsRNA 
RNA viruses, DNA virus 
MDA5 Cytoplasm Long dsRNA RNA viruses (Picornaviridae) 
LGP2 Cytoplasm Unknown RNA viruses 
NLR    
NOD1 Cytoplasm IE-DAP Bacteria 
NOD2 Cytoplasm MDP Bacteria 
CLR    
Dectin-1 Plasma membrane β-glucan Fungi 
Dectin-2 Plasma membrane β-glucan Fungi 
MINCLE Plasma membrane SAP130 Self, fungi 
TLR, toll-like receptor; LPS, lipopolysaccharides; RIG-I, retinoic acid-inducible gene-I; RLR, RIG- I like 
receptor; MDA-5, melanoma differentiation-associated gene 5; NOD, Nucleotide-binding oligomerization 
domain; NLR, NOD-like receptors; MDP, muramyl dipeptide; CLR, C-type lectin receptor; MINCLE, 
macrophage-inducible C-type lectin. 
 
TLR9 
 
TLR9, an intracellular receptor found in endosomes and lysosomes, recognizes 
unmethylated 2´-deoxyribo cytidine-phosphate-guanosine (CpG) DNA motifs that 
frequently exist in bacteria and viruses but are rare in mammalian cells (Hemmi et al., 
2000). 
Synthetic CpG oligodeoxynucleotides (ODNs) containing CpG DNA motif can directly 
activate immune cells such as DCs, macrophages, B cells, and NK cells via TLR9 to 
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release Th1-like cytokines such as IL-12 and IL-18 (Akira et al., 2001). Particularly, 
high expression of TLR9 by plasmacytoid DCs (pDCs) is a sensor of viral DNA to 
induce type I interferon response against viral infection, e.g. murine cytomegalovirus, 
HSV-1 and HSV-2 (Bowie and Unterholzner, 2008; Kawai and Akira, 2006a). TLR9 
also recognizes hemozoin, an insoluble crystalline substance formed in the food vacuole 
of malaria parasite (Coban et al., 2010; Coban et al., 2005).   
 
Other TLRs 
 
Additional TLRs localizing to the cell surface are TLR1, TLR2, TLR5, TLR6, and 
TLR11.   
TLR2 recognizes a variety of microbial components including peptidoglycans, 
lipoproteins and lipopeptides from Gram-negative bacteria and mycoplasma lipopetide. 
TLR2 forms heterodimers with TLR1 or TLR6. TLR2-TLR1 recognizes triacyl-
lipopeptides from Gram-negative bacteria and mycoplasma, whereas the TLR2-TLR6 
dimer recognizes diacyl-lipopeptides from Gram-positive bacteria and mycoplasma 
(Akira et al., 2006). 
TLR5 is expressed by DCs in the small intestine. The receptor recognizes the flagellin 
protein from flagellated bacteria (Hayashi et al., 2001). TLR5 in response to flagellin 
induces the differentiation of naïve T cells into Th17 cells and Th1 cells as well as the 
differentiation of naïve B cells into immunoglobulin A-producing plasma cells (Uematsu 
et al., 2008).     
Other TLRs, such as TLR3, TLR7, and TLR8 are localized to endolysosomal 
compartments and recognize nucleic acids from viruses and bacteria (Kawai and Akira, 
2009; Takeuchi and Akira, 2010). TLR3 is involved in the recognition of synthetic 
analogue of double-stranded (ds) RNA, polyinosinic-polycytidylic acid (poly(I:C)) 
derived from viruses and dsRNA produced during the replication of single-stranded (ss) 
RNA viruses (Alexopoulou et al., 2001). TLR3 induces anti-viral immune responses by 
producing type I IFN and inflammatory cytokines. Mouse TLR7 and human TLR7/8 are 
structurally conserved proteins and they generally recognize ssRNA from RNA viruses 
and synthetic compounds, imidazoquinolines. TLR7 also recognizes RNA species from 
bacteria such as Group B Streptococcus in conventional DCs and induces type I IFN 
(Mancuso et al., 2009). 
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Figure 8. Toll-like receptor signaling pathway. A heterodimer TLR2 and TLR1/TLR6, TLR5/TLR11 
(not shown), and 2 sets of TLR4/MD2 complexes are located on the cell surface for ligand recognition. 
TLR3, TLR7, and TLR9 are located in the endosome. Each receptor specific-ligand stimulation recruits 
MyD88 and TIRAP to all TLRs except TLR3 and a complex of IRAKs and TRAF6 are subsequently 
recruited. TLR3 and TLR4 recruit TRIF and TRAF3 subsequently. TRAF6 activates the TAK1, and the 
activated TAK1 activates IKK complex or the MAPK pathway. The activated TRIF and TRAF3 activate 
TBK1/IKKi, which activate IRF3 and IRF7. MyD88-dependent or independent signaling pathway 
utilmately activates the transcription factors such as AP-1, NF-κB, IRFs inducing proinflammatory 
cytokine genes and the expression of type I IFN genes. Taken from (Takeuchi and Akira, 2010) 
 
TLR signaling pathway 
 
PAMPs-bound TLRs initiate signaling cascades, which are cell specific and dependent 
on different TLRs (Figure 8). TLRs form homo- or heterodimers and facilitate the 
recruitment of TIR domain-containing cytosolic adaptor molecules, such as MyD88, 
toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) (also 
known as MyD88 adaptor like [MAL]), TIR-domain-containing adapter-inducing 
interferon-β (TRIF) (also known as TIR domain-containing adaptor molecule [TICAM-
1]), TRIF-related adaptor molecule (TRAM, also known as TICAM-2) and sterile-alpha 
and Armadillo motif-containing protein (SARM). These adaptor molecules are 
selectively recruited to each TLR. TLR signaling pathway has two distinct pathways 
depending on the adaptor molecules, MyD88 and TRIF (Akira et al., 2006; Kawai and 
   22 
Akira, 2006b; Takeda and Akira, 2004; Takeuchi and Akira, 2010). All TLRs with the 
exception of TLR3 are dependent on MyD88. Certain TLR recruit MyD88 with 
additional adaptor molecules such as TIRAP or TRAM. For example, TLR1, TLR2, 
TLR4, and TLR6 recruit TIRAP, which serves as a linker adaptor between the TIR 
domain of TLR and MyD88. TLR4 binds also TRAM, which further recruits TRIF. 
Upon stimulation, TLR-MyD88 is recruited to IL-1R-associated kinase (IRAK) family 
members, a serine/threonine kinase with an N-terminal death domain. IRAK-4 activates 
IRAK-1 by phosphorylation (Kawagoe et al., 2008) and dissociates from MyD88-TLR 
complex and associate temporarily with TNFR (TRAF-6) leading to its activation by 
forming a complex with ubiquitin-conjugating enzymes. TRAF6 activates the kinase 
complex associating with TGF-β-activated kinase 1 (TAK1), TAK1-binding protein 1 
(TAB1), TAP2, and TAP3, which phosphorylates IKK-β complex leading to nuclear 
translocation of transcription factor NF-κB. Alternatively, the activated TAK1 complex 
enhances the activity of the MAPK pathway, which then activates the transcription 
factor activator protein-1 (AP-1) (Bhoj and Chen, 2009; Kobayashi et al., 2004). 
MyD88-dependent NF-κB activation results in the upregulation of proinflammatory 
cytokine genes including IL-1β, IL-6, and TNF-α (Yamamoto et al., 2004).    
TLR7 and TLR9, expressed by pDCs, also activate the MyD88-dependent pathway to 
stimulate NF-κB and AP-1. Additionally, both receptors induce the production of type I 
IFNs (mainly IFN-α) through the activation of transcription factor IRF7. Direct 
interaction of MyD88 and IRF7 results in a multiprotein signaling complex with IRAK4, 
TRAF6, TRAF3, IRAK1 and IKKα. IRF7 is phosphorylated by IRAK1 and/or IKKα and 
translocated into the nucleus to initiate transcription of the IFN-α gene (Kawai et al., 
2004; Kumagai et al., 2009).  
Alternatively, MyD88-independent components exist for the TLR4 signaling pathway. 
The TRAM-co-interacted adaptor molecule, TRIF controls NF-κB as well as type I IFN 
in MyD88-independent manner. Upon stimulation with dsRNA, TLR3 directly recruits 
TRIF and activates additional molecules leading to IFN secretion. TRIF interacts with 
TRAF6 and RIP1 to activate NF-κB and MAPKs via TAK1. TRIF also recruits TRAF3 
to activate two IKK-related kinases, TBK1 and IKKi, which phosphorylate IRF3 and 
IRF7. These dimers subsequently translocate to the nucleus resulting in the induction of 
type I IFN (Hacker and Karin, 2006; Hacker et al., 2006; Yamamoto et al., 2003).    
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1.3 Alport Syndrome 
 
Alport Syndrome (AS) is a progressive hereditary nephropathy caused by mutations in 
the genes encoding the α3, α4 or α5-chains of type IV collagen (COL4), which disturb 
the normal assembly of GBM (Hudson et al., 1993). AS is characterized by hematuria 
and proteinuria, progressive renal failure, sensorineural deafness, and ocular lesions 
(Hudson et al., 1993; Kashtan, 1998). Cecil A. Alport in 1927 reported that progressive 
hereditary nephritis and deafness were observed in 3 generations of a family and that all 
males and many females were affected (Alport, 1927). The abnormal GBM structure 
activates adjacent glomerular cells. Hence, Alport nephropathy is characterized by an 
increase in glomerular matrix, podocyte detachment, and subsequent glomerular scarring 
(Heidet and Gubler, 2009; Hudson et al., 2003). Like most other types of chronic kidney 
disease, later stages of Alport nephropathy are associated with major tubulointerstitial 
pathology, including mixed interstitial leukocyte infiltrates and interstitial fibrosis 
(Heidet and Gubler, 2009; Jedlicka et al., 2009). 
 
1.3.1 Structure and distribution of type IV collagen 
 
Upon the discovery of type IV collagen by N Kefalides in 1966 (Kefalides, 1966), six 
distinct α-chains have been identified as COL4A1-COL4A6. Each of the six chains of 
collagen IV consists of three domains: a short collagenous domain at the N-terminal 
(known as 7S domain), a long collagenous domain of Gly-X-Y repeats, and a 
noncollagenous domain at the C-terminal (known as NC1). Each chain of collagen IV 
forms three sets of triple helical molecules called protomers, which consist of 
α1α1α2(IV), α3α4α5(IV) and α5α5α6(IV). These protomers associate at the N-terminus 
to form tetramers and at C-terminus to form dimers (NC1-to-NC1) (Figure 9) (Hudson et 
al., 2003). The assembled protomer is flexible and can bend at many triple-helical 
interruption points in the molecule. The collagen protomers create dimer formation via 
their NC1 trimers to form hexamers and four 7S domains form tetramers with 
association of other protomers (Figure 10). Three types of type IV collagen hetero-
trimers are known to exist in mammalian basement membranes following as 
α1α1α2(IV)-α1α1α2(IV), α3α4α5(IV)-α3α4α5(IV), and α1α1α2(IV)-α5α5α6(IV).  
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Figure 9. Type IV collagen network formation 
Six genetically distinct α chains (α1-α6) are composed of three domains: a minor amino-terminal 7S 
domain (about 140 residues), a major triple helical collagenous domain in the middle within Gly-X-Y 
amino acid sequence (about 1,400 residues), and a carboxyl-terminal noncollagenous domain (about 230 
residues). Type IV collagen α chains can be assembled into trimeric protomers called as protomers when 
the three NC1 domains initiate triple helice interactions. Taken from (Hudson et al., 2003).  
  
 
 
Figure 10. Assembly and network organization of collagen IV protomers  
Protomers create basement-membrane networks with other protomers by uniting two NC1 trimers to form 
an interface hexamer at the C-terminal and by uniting four triple helical 7S domains at the N-terminal. A 
network composed of α3.α4.α5(IV) protomers is illustrated, showing end-to-end connections of individual 
protomer units, supercoiling and looping of the triple helixes, and disulfide cross-links between triple 
helical domains. The structure of the NC1 hexamer is determined by the particular α chains that form a 
triple helical protomer and by the particular canonical protomers that can connect to adjoining protomers 
(NC1 box). Molecular recognition sequences encoded within NC1 domains govern the selection of partner 
chains for both protomer and network assembly. The 7S domains also play a key part in determining the 
specificity, affinity, and geometry of the tetramer formed through the connection of four protomers (7S 
box). Two other networks are composed of pairs of α1.α1.α2(IV) hexamers or α1.α1.α2(IV)–α5.α5.α6(IV) 
NC1 hexamers.  The α3.α4.α5(IV)–α3.α4.α5(IV) network differs from the others in that it has a greater 
number of disulfide cross-links between triple helical domains, which increases its resistance to 
proteolysis. Taken from (Hudson et al., 2003). 
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Table 4. . Genetic forms of Alport syndrome 
Genetic forms Mutation Clinical description 
X-linked 
(XLAS) 
The most common 
form (80-85%) 
 
Adult COL4A5 gene Delay onset of renal failure (>30yr of age) 
Mild deafness in men; less severe in female carriers 
Juvenile COL4A5 gene Early onset of renal failure (<30 yr of age) 
Frank deafness ad often lenticonus in men 
Autosomal recessive 
(ARAS) 
10-15% 
COL4A3 or 
COL4A4 
Early onset of renal failure (<30 yr of age) in both sexes 
Autosomal 
dominant 
(ADAS) 
Rare form, 5% 
COL4A3 or 
COL4A4 
Renal failure of varying severity 
 COL, collagen 
 
The α1α1α2(IV)-α1α1α2(IV) network is found in all basement membranes, whereas  
other types of the network have a restricted distribution in mammalian tissues. The 
α3α4α5(IV) network is the predominant component of GBM as well as the Bowman´s 
capsule and the basement membranes of distal and collecting tubules. It is also found in 
non-kidney parts, e.g. eye and inner ear (Kalluri et al., 1998; Kalluri et al., 1997). The 
α1α1α2(IV)-α5α5α6(IV) network is present in Bowman´s capsule and in basement 
membranes surrounding smooth muscle cells of vessels and viscera (Borza et al., 2001; 
Harvey et al., 1998; Yoshioka et al., 1994). 
 
1.3.2 Genetics of Alport Syndrome 
 
Mutations in the α3, α4, and α5 chains of type IV collagen of the basement membranes 
can cause Alport syndrome. There are three genetic types of Alport syndrome: XLAS 
(X-linked Alport syndrome), ARAS (autosomal recessive Alport syndrome) and ADAS 
(autosomal dominant Alport syndrome) (Table 4). XLAS is the most common type that 
accounts for 80%–85% of the cases and caused by mutations in the COL4A5 gene 
(Barker et al., 1990; Kashtan, 1998). This gene is located on X-chromosome, therefore, 
inherited males are severely affected, whereas females are carriers or usually have 
milder symptoms. The autosomal recessive variant comprises about 15% of the cases, 
and results from homozygous or compound heterozygous mutations in the COL4A3 or 
COL4A4 gene (Lemmink et al., 1994; Longo et al., 2002; Mochizuki et al., 1994). A 
rarely reported form of Alport syndrome is the autosomal dominant Alport syndrome, 
which is caused by mutations in either the COL4A3 or COL4A4 gene (Pescucci et al., 
2004).  
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1.3.3 Clinical and pathologic features of Alport Nephropathy 
 
Mutations in the COL4A3, COL4A4 or COL4A5 genes result in loss or abnormal 
assembly of the α3(IV), α4(IV) or α5(IV) chain, respectively. These mutations, 
therefore, arrest the normal developmental switch from the α1α1α2 network to the 
α3α4α5 network causing a failure of formation of the α3α4α5 protomer, and lead to an 
absence of the α3α4α5 network which is necessary to create a mature basement 
membrane. In the glomerulus, these chains are synthesized by podocytes (Heidet et al., 
2000). Animal studies for AS have shown that the α1α1α2 network is essential for 
normal glomerular development, whereas the α3α4α5 network is not, but is crucial for 
long-term maintenance of glomerular structure and function (Harvey et al., 1998). The 
embryonic α1α1α2 network is more susceptible to proteolysis by e.g. the matrix 
metalloproteinase (MMP) family of endopeptidases than the α3α4α5 network which is 
more resistant to proteolysis. Thus, it may explain that Alport GBM is more susceptible 
to preoteolysis because of the absence of the α3α4α5 network (Hudson, 2004). Studies 
of animal and human AS have also documented that the MMP-12 expression was 
increased in podocytes (Rao et al., 2006a). The progressive proteolysis of GBM leads to 
irregular thickening of the glomerular membrane and the outer slit diaphragm formed 
between adjacent podocytes. Ultimately, the GBM deteriorates producing proteinuria. 
Thus, renal failure in many Alport patients involves the progressive proteinuria leading 
to glomerulosclerosis including podocyte loss, and tubulointerstitial damage with tubular 
atrophy and interstitial fibrosis. 
Kidneys from patients with Alport syndrome are always affected. The primary 
observation in all affected males and most of females with XLAS in early childhood is 
the presence of blood in the urine (hematuria), which is usually persistent microscopic 
and sometimes shows episodic gross hematuria (Kashtan, 1998). As children with Alport 
syndrome get older, they develop additional symptoms of kidney disease, e.g. the 
presence of protein in the urine (proteinuria) and hypertension. Proteinuria occurs in all 
males with XLAS and in both males and females with ARAS. All teen-aged boys have 
these symptoms. By contrast, only occasionally they appear in girls with Alport 
syndrome (Jais et al., 2003; Jais et al., 2000). Progressive increase of proteinuria causes 
damage to the kidneys and it eventually leads to ESRD in all affected males with XLAS 
(Jais et al., 2000). Diagnostic renal biopsy studied by electron microscopy indicate 
diffused irregular thickness of the GBM, consisting of variable thinning and thickening, 
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as well as splitting or fraying of the lamina densa. Immunohistological analysis by 
staining for type IV collagen α chains is also available to display the expression of 
collagen IV α chains. 
 
1.3.4 Animal models of Alport Syndrome 
 
Several animal models of Alport syndrome have been established to understand the 
disease mechanisms and to provide opportunities for testing potential therapies (Gross 
and Kashtan, 2009; Kashtan, 2002). Two dog models for the most common type of 
Alport syndrome (XLAS) have been identified and characterized. A mutation in 
COL5A5 gene in Samoyed breed has been discovered (Zheng et al., 1994) and a second 
model has been described in a mixed breed of dogs from Navasota, Texas (Lees et al., 
1999). Other canine models for autosomal-recessive and dominant AS have also been 
found but the mutation has not yet been identified.   
Several murine Alport models have also been generated. Autosomal recessive models 
which have mutations in COL4A3 and/or COL4A4 gene have been developed 
(Cosgrove et al., 1996; Miner and Sanes, 1996). Recently, another mouse model 
targeting the COL4A5 gene for XLAS has been produced in the C57BL/6 background 
(Rheault et al., 2004).  
  
1.3.5 Mouse autosomal recessive Alport model 
 
An autosomal recessive Alport mouse model was generated by gene targeting at the 
Col4a3 locus. Two different strains of mouse models are described in both the129/SvJ 
and the C57BL/6J background (Cosgrove et al., 2007; Gross et al., 2009).  
The onset of glomerular disease and the rates of progression to ESRD are different 
depending on the genetic background. The rate of progression to ESRD in the 129/SvJ 
background is much more rapid as compared to the C57BL/6J background (around 3 
fold difference on life span, Figure 11A). Identification of GBM composition by e.g. 
immunostaining of different type IV collagen α chains in Alport mouse kidneys suggests 
the influence of strain-dependent differences. During development of the murine 
embryonic GBM, the α1α2(IV) collagen network switches to alternative isoform of the 
robust α5α6(IV) network in Col4a3-deficient mice in the C57BL/6J background, 
whereas this is very weak in mice with the 129/SvJ background (Figures 11B and C). 
(Cosgrove et al., 2007; Gross et al., 2009; Kang et al., 2006). 
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A                                                                              B 
 
 
C 
 
 
Figure 11. Pathologic and molecular differences depending on the genetic background in Col4a3-
deficient mice. (A) Life span depends on the different strains. (B) Isoform switches of type IV collagen 
network (C) Immunostaining of different type IV collagen chains in Col4a3-deficient mice kidneys. A and 
C were taken from (Gross et al., 2009), and B was taken from (Cosgrove et al., 2007). 
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1.3.6 Treatment of Alport syndrome 
 
Present and future therapeutic targets for CKD might be against inflammation, fibrosis, 
and glomerular injury (Perico et al., 2008). Particularily, most of glomerular diseases 
associated with nephrotic sydrome in CKD are characterized by heavy proteinuria 
leading to glomerulosclerosis (Remuzzi et al., 2006b). Antiproteinuric treatments based 
on angiotensin (AT) II antagonism are mostly available for regression of glomerular 
lesions in animals and patients with CKD (Macconi et al., 2009; Perico et al., 2008; 
Remuzzi et al., 2006a). In Alport syndrome, several animal studies have also suggested 
potential effect of angiotensin-converting enzyme (ACE) inhibition (Gross et al., 2003; 
Gross et al., 2004) and AT1-receptor blockade (ARB) (Gross et al., 2003; Gross et al., 
2004) because massive proteinuria is main cause of  progression of Alport disease. 
However, till date there are no substantial therapies for human AS. Only ACE inhibition 
has been shown to be effective in human AS. Recent studies have shown that ACE 
inhibition delayed the renal failure and improved life expectancy in patients with AS 
(Gross et al., 2012; Kashtan et al., 2012).  
Many other animal studies have also shown that a variety of effective therapies including 
anti-TGF-β1 antibody (Cosgrove et al., 2000), inhibition of matrix metalloproteinases 
(Zeisberg et al., 2006), vasopeptidase inhibition (Gross et al., 2005), HMG-CoA 
reductase inhibition (Koepke et al., 2007), chemokine receptor 1 blockade (Ninichuk et 
al., 2005), BMP-7 (Zeisberg et al., 2003), and stem cells (Ninichuk et al., 2006; 
Sugimoto et al., 2006) to improve Alport kidney disease. However, these approaches 
have yet to be clinically tested in people with AS. There is a need to understand the 
pathomechanisms of the progression of AS and to clinically evaluate the novel 
therapeutic targets for AS. We have tried to understand the role of various factors 
contributing to podocyte loss in Alport nephropathy. Elevated proteinuria and podocyte 
loss are main clinically important aspects of AS. It would be worth understanding the 
contributing factors like infiltrating leukocytes, various proinflammatory cytokines and 
TLR activation (innate immune response) to podocyte loss. This approach will help us to 
improve the clinical aspects of patients with chronic kidney disease such as AS. At the 
same time it helps us to find novel therapeutic targets.   
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2. Hypothesis/Objectives 
Several factors contribute to final remodeling in chronic kidney disease. Here, I used 
Col4a3-deficient mice with Alport nephropathy as a CKD animal model to understand 
the pathologic mechanisms of disease progression. Alport nephropathy is a non-
inflammatory renal disease which involves severe glomerulosclerosis accompanied by 
progressive loss of parenchymal cells. Podocytes are terminally differentiated 
glomerular epithelial cells which are rarely replaced after injury. The aim of this study 
was to determine endogenous and extrinsic factors that might induce podocyte loss 
during Alport kidney disease in Col4a3-deficient mice. Finally, these findings can 
contribute to identification of novel therapeutic targets for Alport nephropathy. 
 
1. Leukocyte infiltrates are found in Alport mice. It is known that infiltrating leukocytes 
are the main source of proinflammatory and proapoptotic cytokines/chemokines. Here, I 
speculated that the proapoptotic cytokine, TNF-α is primarily produced by infiltrating 
leukocytes and probably by intrinsic renal cells as well. Furthermore, TNF-α contributes 
to podocyte loss and glomerular injury in the progression of Alport nephropathy. 
 
2. Extrinsic factors, e.g. infections resulting in TLR activation, accelerate the 
progression of chronic kidney disease by inducing expression of a variety of cytokines, 
chemokines and proapototic factors. Leukocytes and renal cells are known to express a 
variety of TLRs.  First, I hypothesized activation of TLR on renal fibroblasts contributes 
the aggravation of Alport nephropathy by inducing the expression of proinflammatory 
and profibrotic molecules.  
 
3. Macrophages may be involved in disease aggravation of Alport nephropathy. I 
speculated that TLR agonists alter the macrophage phenotypes towards M1 macrophages 
and worsen the glomerular damage in Alport nephropathy. To address this issue, I 
determined TLR activation and macrophage phenotype by injecting LPS as a TLR4 
agonist and CpG-DNA as a TLR9 agonist into Col4a3-deficient mice. I also determined 
the question whether these factors can regulate TNF-α signaling, which may induce 
podocyte loss.  
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3. Materials and Methods 
 
3.1 Materials 
 
3.1.1 Equipment  
 
Balances  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
Cell Incubators  
Type B5060 EC-CO2    Heraeus Sepatech, München, Germany 
Centrifuges  
Heraeus, Minifuge T  VWR Internationl, Darmstadt, Germany 
Heraeus, Biofuge primoKendro             Laboratory Products GmbH, Hanau, Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
ELISA-Reader  
Tecan, GENios Plus               Tecan, Crailsheim, Germany 
Fluorescence Microsocopes  
Leica DC 300F             Leica Mycrosystems, Cambridge, UK 
Olympus BX50 Olympus Microscopy, Hamburg, Germany 
Spectrophotometer  
Beckman DU® 530 Beckman Coulter, Fullerton, CA, USA 
NanoDrop 1000 Thermo Fisher Scientific, Wilmington, DE, 
USA 
Real-Time PCR System   
Light Cycler 480 Roche, Mannheim, Germany 
Other Equipments  
Homogenizer 
ULTRA-TURRAX T25 
IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436    Eppendorf, Hamburg, Germany 
Vortex Genie 2™    Bender&Hobein AG, Zurich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
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3.1.2 Chemicals and materials 
Chemicals  
Aceton  Merck, Darmstadt, Germany 
Bovines Serum Albumin                               Roche Diagnostics, Mannheim, Germany 
Calcium chloride                                           Merck, Darmstadt, Germany 
Calcium dihydrogen phosphate                Merck, Darmstadt, Germany 
DAPI                                                            Vector Laboratories Inc, Burlingame, USA 
D-Glucose                                                      Merck, Darmstadt, Germany 
DEPC                                                             Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
EDTA Calbiochem, SanDiego, USA 
Ethanol Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Magnesium chloride·6H2O Merck, Darmstadt, Germany 
Magnesium sulfate·7H2O Merck, Darmstadt, Germany 
Mercaptoethanol Roth, Karlsruhe, Germany 
Potassium chloride Merck, Darmstadt, Germany 
Potassium phosphate monobasic Merck, Darmstadt, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Sodium acetate  Merck, Darmstadt, Germany 
Sodium azide Roth, Karlsruhe, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate  Merck, Darmstadt, Germany 
Sodium dihydrogen phosphate  Merck, Darmstadt, Germany 
Sodium hydrogen carbonate Merck, Darmstadt, Germany 
Sodium phosphate dibasic dihydrate  Merck, Darmstadt, Germany 
Tris Roth, Karlsruhe, Germany 
Trypan Blue     Sigma-Aldrich, Steinheim, Germany 
Tween 20          Sigma-Aldrich, Steinheim, Germany 
Oxygenated water     DAKO, Hamburg, Germany 
Xylol    Merck, Darmstadt, Germany 
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• All other reagents were of analytical grade and are commercially available from 
Invitrogen, SIGMA or ROTH. 
Chemicals for the molecular biology techniques 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
 Invitrogen, Karlsruhe, Germany 
 
 
ELISA kits  
Mouse IL6 BD OptEiA, San Diego, CA, USA 
Mouse MCP-1 BD OptEiA, San Diego, CA, USA 
Mouse Albumin Bethyl Laboratories, TX, USA 
Mouse TGF-beta R &D Systems, Minneapolis, MN, USA 
  
In Situ Cell Death Detection Kit, 
Fluorescein (TUNEL assay) 
Roche, Mannheim, Germany 
 
  
Creatinine FS Diagnostic Systems, Holzheim, Germany 
Urea FS Diagnostic Systems, Holzheim, Germany 
  
Cell culture   
DMEM-medium GIBCO/Invitrogen, Paisley, Scotland, UK 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
FCS Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×) PAA Laboratories GmbH, Cölbe,Germany 
Trypsine/EDTA (1×) PAA Laboratories GmbH, Cölbe,Germany 
Penicillin/Streptomycin (100×) PAA Laboratories GmbH, Cölbe,Germany 
 
Antibodies 
anti-CD3ε-FITC (Clone 145-2C11)                          BD Pharmingen, Heidelberg, Germany 
anti-CD4-APC (Clone RM4-5)                                 BD Pharmingen, Heidelberg, Germany 
anti-CD8a-PerCp (Clone 53-6.7)                               BD Pharmingen, Heidelberg, Germany 
anti-CD11b-APC or PE (Clone M1/70)                    BD Pharmingen, Heidelberg, Germany 
anti-CD11c-FITC or PE (Clone HL3)                       BD Pharmingen, Heidelberg, Germany 
anti-CD45-PE (Clone 30-F11) BD Pharmingen, Heidelberg, Germany 
anti-F4/80-APC (Clone Cl:A3-1) Serotec, Oxford, UK 
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anti-Ly6C-FITC (Clone AL-21) BD Pharmingen, Heidelberg, Germany 
anti-Ly6G-FITC (Clone 1A8) BD Pharmingen, Heidelberg, Germany 
anti-Ly6G/C (Gr-1)-APC  
(Clone RB6-8C5) 
BD Pharmingen, Heidelberg, Germany 
Anti-TNF-α-APC (clone MP6-XT22) BD Pharmingen, Heidelberg, Germany 
anti-CD90-PE (Clone 30-H12)    Acris Antibodies, Hiddenhausen, Germany 
 
 
Antibodies for immunohistochemistriy 
Rat anti-CD45                           Dianova, Hamburg, Germany 
Rat anti-F4/80  Serotec, Oxford, UK 
Rat anti-Mac2   Cederlane, Ontario, Canada 
guinea pig anti-nephrin Acris Antibodies, Herford, Germany 
Goat anti-TNF-α R&D Systems, Minneapolis, MN, USA 
Rat anti-Wilms Tumor (WT)-1 Santa Cruz, Santa Cruz, CA, USA 
  
Secondary Antibodies for immunohistochemistriy 
Cy3® goat anti-rat IgG (H+L) Invitrogen, Karlsruhe, Germany 
Alexa Fluor® 488 goat anti-guinea pig 
IgG (H+L) 
Invitrogen, Karlsruhe, Germany 
Alexa Fluor® 555 goat anti-guinea pig 
IgG (H+L) 
Invitrogen, Karlsruhe, Germany 
  
Magnetic Activated Cell Sorting (MACS) 
Anti-PE MicroBeads Miltenyi Biotec, Bergish Gladbach, Germany 
Mouse CD11b MicroBeads 
 
MACS LS column 
 
QuadroMACS™ Separator  
 
 
Miscellaneous  
Needles BD Drogheda, Ireland 
Nunc Maxisorp ELISA plate Nunc, Wiesbaden, Germany 
Pipette’s tip 1-1000µL Eppendorf, Hamburg, Germany 
Plastic histosettes NeoLab, Heidelberg, Germany 
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Preseparation filters Miltenyi Biotec, Bergish Gladbach, Germany 
Silver Impregnation Kit Bio-Optica, Milano, Italy 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Tissue culture dishes  Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes  Ø 35x10mm  TPP, Trasadingen, Switzerland 
Tissue culture flasks 150 cm2 Becton Dickinson, Franklin Lakes, NJ, USA 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland 
 
 
RT-PCR primers Metabion, Martinstried, Germany 
      
Gene Accession Sequence 
18s NR_003278 Forward: GCAATTATTCCCCATGAACG 
Reverse: AGGGCCTCACTAAACCATCC 
Acta2 
(α-sma) 
NM_007392 Forward: ACTGGGACGACATGGAAAAG 
Reverse: GTTCAGTGGTGCCTCTGTCA 
Arg1 NM_007482 Forward: AGAGATTATCGGAGCGCCTT 
Reverse: TTTTTCCAGCAGACCAGCTT 
Ccl2 NM_011333 Forward: CCTGCTGTTCACAGTTGCC 
Reverse: ATTGGGATCATCTTGCTGGT 
Ccl5 NM_013653 Forward: CCACTTCTTCTCTGGGTTGG 
Reverse: GTGCCCACGTCAAGGAGTAT 
Ccl22 NM_009137 Forward: TCTGGACCTCAAAATCCTGC 
Reverse: TGGAGTAGCTTCTTCACCCA 
Col1a1 NM_007742 Forward: ACATGTTCAGCTTTGTGGACC 
Reverse: TAGGCCATTGTGTATGCAGC 
Cxcl10 NM_021274 Forward: GGCTGGTCACCTTTCAGAAG 
Reverse: ATGGATGGACAGCAGAGAGC 
Fizz-1 
(Retnla) 
NM_020509 Forward: CCCTTCTCATCTGCATCTCC 
Reverse: CTGGATTGGCAAGAAGTTCC 
IL6 NM_031168 Forward: TGATGCACTTGCAGAAAACA 
Reverse: ACCAGAGGAAATTTTCAATAGGC 
IL10 NM_010548 Forward: ATCGATTTCTCCCCTGTGAA 
Reverse: TGTCAAATTCATTCATGGCCT 
   36 
Gene Accession Sequence 
IL12 
(Il12p35) 
NM_008351 Forward: CTAGACAAGGGCATGCTGGT 
Reverse: GCTTCTCCCACAGGAGGTTT 
IL12 
(Il12p40) 
NM_008352 Forward: AGCAGTAGCAGTTCCCCTGA 
Reverse: AGTCCCTTTGGTCCAGTGTG 
Mrc1 NM_008625 Forward: ATATATAAACAAGAATGGTGGGCAGT 
Reverse: TCCATCCAAATGAATTTCTTATCC 
Nos2 
(iNos) 
NM_010927 Forward: TTCTGTGCTGTCCCAGTGAG 
Reverse: TGAAGAAAACCCCTTGTGCT 
Nphs1 
(nephrin) 
NM_019459 Forward: TTAGCAGACACGGACACAGG 
Reverse: CTCTTTCTACCGCCTCAACG 
Nphs2 
(podocin) 
NM_130456 Forward: TGACGTTCCCTTTTTCCATC 
Reverse: CAGGAAGCAGATGTCCCAGT 
Tgf-β1 NM_011577 Forward: GGAGAGCCCTGGATACCAAC 
Reverse: CAACCCAGGTCCTTCCTAAA 
Tnf-α 
 
NM_013693 
 
Forward: CCACCACGCTCTTCTGTCTAC 
Reverse: AGGGTCTGGGCCATAGAACT 
Ym1 
(Chi3l3) 
NM_009892 Forward: TCTGGGTACAAGATCCCTGAA 
Reverse: TTTCTCCAGTGTAGCCATCCTT 
 
3.1.4 Solutions 
 
Anesthesia mixture 
Isoflurane Harvard Anesthesia System, UK 
                                                                               
Genotyping 
1x PBND buffer 
50 mM KCL 
10 mM Tris-HCL, pH 8.3 
2.5 mM MgCl2 
0.01 % w/v gelantin 
0.45 % v/v Nonidet P40 
0.45 % v/v Tween20 
H2O 
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Proteinase K                    MercK 
 
MACS Buffer 
PBS pH 7.2 
0.5 % bovine serum albumin 
2 mM EDTA 
  
10x PBS, pH 7.4 
1.37 M NaCl 
27 mM KCl 
0.1 M KH2PO4 
18 mM Na2HPO4 
 
FACS anaylsis 
FACS-buffer 
500 ml D-PBS + 0.2 % BSA + 0.1 % Na Azide 
 
Paris-buffer, pH 7.4 
20 mM Tris-HCl 
125 mM NaCl 
10 mM KCl 
10 mM Na-Acetate 
5 mM Glucose 
 
10x HBSS (Hank´s balanced saline solution) with Ca, Mg, pH 7.4 
54 mM KCl 
4.4 mM KH2PO4 
1.37 M NaCl  
3.5 mM Na2HPO4·2H2O 
42 mM NaHCO3 
13 mM CaCl2 
4.9 mM MgCl2·6H2O 
4.1 mM MgSO4·7H2O 
55 mM D-Glucose 
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10x HBSS without Ca, Mg 
54 mM KCl 
4.4 mM KH2PO4 
1.37 M NaCl  
3.5 mM Na2HPO4·2H2O 
 
DNase-stock solution (1 mg/ml) 
DNase (Type IV) 15.000 U/6 mg, Sigma-Aldrich, Steinheim, Germany 
Reconstitute 6 mg of DNase with 6 ml of 50 % glycerol solution. 
 
50 % (w/v) glycerol solution in 20 mM Tris/HCl, pH 7.5, 1 mM MgCl2 
40 mM Tri-buffer in 100 ml H2O, pH 7.4  
50 mM Glycerol 100 % + 20 mM Tris-buffer  
1 M MgCl2 
 
Collagenase/DNase solution 
1 mg/ml Collagenase (Type I, Sigma-Aldrich, Steinheim, Germany), 0.1 mg/ml DNase 
in 1x HBSS (with Ca, Mg) 
10 mg Collagenase 
1 ml DNase-stock (1 mg/ml) 
9 ml 1x HBSS (with Ca, Mg) 
- Warm in waterbath at 37 °C 
 
Collagenase solution 
10 mg Collagenase 
10 ml 1x HBSS (with Ca, Mg) 
- Warm in waterbath at 37 °C 
    
2 mM EDTA 
7.44 mg EDTA + 10 ml 1x HBSS (w/o Ca, Mg) 
Or 100 µl of 0.2 M EDTA solution + 10 ml 1x HBSS 
- Warm in waterbath at 37 °C 
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3.2 Methods 
 
3.2.1 Animal studies 
3.2.1.1 Homing conditions and animal procedures 
 
Col4a3-deficient and wildtype littermate mice in identical 129/SvJ genetic backgrounds 
were selected from the available Alport disease models because of their consistent 
phenotype leading to uremic death at about 10 weeks of age (Cosgrove et al., 1996). 
Mice were housed in filter top cages with a 12 hour dark/light cycle and unlimited access 
to food (Sniff, Soest, Germany) and water for the duration of the study. Cages, bedding, 
food, and water were sterilized by autoclaving before use and genotyped as described 
(Ninichuk et al., 2005). All experimental procedures were performed according to the 
German animal care and ethics legislation and were approved by the local government 
authorities. 
 
3.2.1.2 Study design and experimental procedures 
 
For a first study, 4-week-old Col4a3-deficient and wildtype mice were treated with 
intraperitoneal injections of etanercept at 100 µg/mouse 3 days per week for 5 weeks and 
the other mice were treated with either saline or the same amount of human IgG as a 
vehicle or a control, respectively. One cohort of Col4a3-deficient mice (n=9) was 
monitored to determine life span and another cohort was sacrificed at 9-week-old for 
histopathological evaluation.  
 
For a second study, at the age of 4 weeks groups of Col4a3-deficient and wildtype mice 
were started to receive seven intraperitoneal injections on alternate days of either 100 µl 
normal saline (vehicle), 10 µg of ultrapure LPS (Invivogen, San Diego, CA) in vehicle 
or 40 µg endotoxin-free CpG-phosphothioate oligonucleotide 1668 (5`-TCG ATG ACG 
TTC CTG ATG CT-3`, TIB-Molbiol, Berlin, Germany) in vehicle. The doses of both 
TLR agonists were selected because they induced identical serum levels of IL-6 and 
CCL2/MCP-1 6 hours after intraperitoneal injection. One cohort of mice was bled and 
sacrificed at 6 weeks of age. Another cohort was followed until death in order to 
determine life span. An additional cohort of CpG-DNA-treated Col4a3-deficient mice 
was intraperitoneally injected with either saline or 100 µg etanercept (Wyeth, Taplow, 
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Maidendead, UK) every other day from week 4 to 6 to block TNF-α (Karkar et al., 2001; 
Lech et al., 2009).  
 
Urine and plasma samples from all mice were collected at weekly intervals and used for 
renal function estimations.  
 
3.2.1.3 Plasma and urine sample analysis 
 
Blood samples were collected under isoflurane anesthesia by retroorbital bleeding using 
heparinised capillaries. Plasma was separated using EDTA (10 µl of 0.5 M solution per 
200 µl of blood) by centrifugation at 8000 rpm for 5 minutes and stored at -20 °C until 
used for different cytokine estimations.  
Urine samples were collected every alternate week or at study termination from each 
mouse in microcentrifuge tubes and were stored at -20 °C until used for different 
biochemical estimations as described (Anders et al., 2003b; Sayyed et al., 2009). 
 
Urinary albumin 
 
Urinary albumin levels were determined using albumin ELISA kit from Bethyl 
laboratories following manufacturer’s instructions. Urine samples from mice were 
diluted 1000 times with assay diluent before estimation. In brief, immuno 96 well solid 
plate (Nunc, Wiesbaden, Germany) was coated with capture antibody (Anti-Mouse 
albumin, 1:100 dilution) diluted in carbonate-bicarbonate (pH 9.6) coating buffer and 
incubated overnight at 4 °C. The plate was washed 3 times with wash buffer (Tris NaCl 
with 0.05 % Tween 20) and blocked with blocking solution (Tris NaCl with 1 % BSA, 
pH 8) at room temperature for 1 hour. Blocked plate was washed 5 times with wash 
buffer and then diluted samples/standards were transferred into assigned wells and 
further incubated for 1 hour. After incubation the plate was again washed 5 times and 
diluted HRP-conjugated detection antibody (using the suggested dilution) was added and 
the plate was incubated in the dark for further 1 hour. After HRP-conjugate incubation 
was over each well was washed 5 times and 100 µl of Substrate Solution (1:1, 
Teteramethylbenzidine (TMB):Hydrogen Peroxide, TMB Substrate reagent, BD 
Biosciences, Heidelberg, Germany) was added to each well and incubated without plate 
sealer for about 30 minutes at room temperature in the dark. The reaction was stopped 
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by addition of stop solution (2 N H2SO4). The absorbance was read at 450 nm within 10 
minutes of stop solution addition. The albumin content in each sample was determined 
using the equation of regression line generated by plotting absorbance of different 
standards against their known concentrations. 
 
Urinary creatinine measurement 
 
Urinary creatinine levels were measured using enzymatic reaction (Jaffe’ reaction using 
biochemical kit from Diasys Diagnostic Systems, Holzheim, Germany). Urine samples 
were diluted 10 times with distilled water. Different dilutions of standard were prepared 
using the stock provided with the kit. Working monoreagent was prepared by mixing 4 
parts of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. 10 µl of each 
of the diluted samples and standards were added to a 96 well plate with flat bottom 
(Nunc maxisorb plate). 200 µl of monoreagent was added to each well and absorbance 
was read at 490 nm immediately after and 1 (A1) and 2 (A2) minutes of addition using 
ELISA plate reader. The change in absorbance (∆ A) was calculated   as ∆ A = [(A2 – 
A1) sample or standard] – [(A2 – A1) blank]. Creatinine content of samples was 
calculated as: 
 
Creatinine (mg/dl) = ∆A sample /∆A standard * Concentration of standard (mg/dl) 
 
 
Urinary albumin to creatinine ratio (UACR) 
 
Urinary albumin to creatinine ratio was calculated after converting values for albumin 
and creatinine to similar units (mg/dl). Albumin content for each sample calculated 
(mg/dl) was divided by creatinine content (mg/dl) for the same sample.  
 
 
Plasma creatinine and blood urea nitrogen determination 
 
Blood urea nitrogen (BUN) in plasma was measured using a commercially available kit 
(DiaSys Diagnostic Systems). Plasma samples and standard were added to a 96 well 
plate and 200 µl of monoreagent was added and absorbance of A1 and A2 was read at 
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360 nm using ELISA plate reader. The change in absorbance (∆ A) was calculated   as ∆ 
A = [(A1 – A2) sample or standard] – [(A1 – A2) blank]. And BUN content of samples 
was converted from urea content calculated as: 
 
Urea (mg/dl) = ∆A sample /∆A standard * concentration of standard (mg/dl) 
 
BUN (mg/dl) = Urea (mg/dl) * 0.467 
 
 
Glomerular filtration rate  
 
Glomerular filtration rate in conscious mice was determined using fluorescein 
Isothiocyanate-inulin (FITC-inulin) clearance from plasma after single bolus intravenous 
injection (Ninichuk et al., 2008). In short, 5 % FITC-inulin was dissolved in 0.9 % NaCl 
facilitated by heating at 65 °C and dialyzed through the 1 kDa dialysis membrane 
(Spectra/Pro 6, Spectrum Laboratories Inc., Rancho Dominguez, CA) in 0.9 % NaCl 
overnight at room temperature. Prior to use, the dialyzed solution was filtered through a 
0.22 µm filter. Animals were anesthetized using isoflurane for short duration, and 5 % 
FITC-inulin solution was rapidly injected retroorbitally (3.74 µl/g body weight). Blood 
samples were drawn at different time point (5, 10, 15, 20, 35, 60 and 90 minutes post 
inulin injection). Blood samples were centrifuged at 8000 rpm for 5 minutes and plasma 
was separated. Each plasma sample was buffered to pH 7.4 by mixing 10 µl of plasma 
with 40 µl of 500 mM HEPES buffer (pH 7.4) in 96 well plates. Fluorescence was 
determined using excitation filter having wave length of 485 nm while read filter was set 
at wave length of 535 nm. 
For GFR calculation two-compartment clearance was employed. In two compartment 
model the initial, rapid decay phase represents redistribution of tracer from the 
intravascular compartment to extracellular fluid. Later, slower decay in concentration of 
the tracer due to systemic clearance from plasma predominates. At any given time (tx), 
the plasma concentration of the tracer (Y) can be calculated as  
 
Y = Ae-αtx +Be-βtx  + Plateau 
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Where, 
Y is plasma concentration of tracer 
A is y-intercept of fast decay rate (SPAN1) 
B is y-intercept of slow decay rate (SAPN2) 
α is fast decay rate constant 
β is slow decay rate constant 
 
Figure 12. Representation two phase regression curve  
 
These parameters were calculated using non-linear curve-fitting program (GraphPad 
Prism, GraphPad Software Inc, San Diego, CA, USA) followed by exponential two-
phase decay with plateau set as zero. 
 
GFR was calculated as:  
GFR = I / (A/α +B/β) 
 
Calculated GFR was reported as ml/min and was expressed as mean ± SEM for each 
group. 
 
3.2.1.4 Immunohistochemical  methods and histopathological evaluation 
 
Parts of the kidneys were fixed in 10 % formalin in phosphate-buffered saline (PBS) and 
embedded in paraffin. 2 µm sections were cut and processed for staining with periodic 
acid-Schiff reagent. Glomerular sclerotic lesions were assessed using a semiquantitative 
score by a blinded observer as follows: 0 = no lesion, 1 = <25 % sclerotic, 2 = 25-49 % 
sclerotic, 3 = 50-74 % sclerotic, 4 = 75-100 % sclerotic, respectively. 15 glomeruli were 
analysed per section (Ninichuk et al., 2006).  
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All immunohistological studies were performed after deparaffinisation. Dehydration was 
carried out by incubating the sections in xylene, 100 % absolute ethanol, 95 %, 80 % and 
50 % ethanol followed by rinsing with PBS (2 changes, 3 minutes each). The following 
antibodies were used as primary antibodies: rat anti-Mac2 (glomerular macrophages, 
Cederlane, Ontario, Canada, 1:50), rat anti-F4/80 (interstitial macrophages, Serotec, 
Oxford, UK, 1:50), rat anti-CD45 (leukocytes, Dianova, Hamburg, Germany, 1:25), rat 
anti-Wilms Tumor (WT)-1 (podocytes, Santa Cruz, Santa Cruz, CA, USA, 1:25), goat 
anti-mTNF-α (R&D Systems, Minneapolis, MN, USA, 1:200). For immunofluorescece 
staining, rat anti-Wilms Tumor (WT)-1 and guinea pig anti-nephrin (Acris Antibodies, 
Herford, Germany, 1:100) were used as primary staining. Cy3® goat anti-rat IgG (H+L) 
(Invitrogen), for WT-1 detection and Alexa Fluor® 488 goat anti-guinea pig IgG (H+L) 
(Invitrogen) for nephrin detection were used as secondary antibodies.  
Glomerular cell counts evaluated only cells of the tuft from 50 glomeruli and interstitial 
cells were counted in 15 high power fields (hpf, 400x).  
 
3.2.1.4 Electron microscopy 
 
For ultrastructural analysis, kidney specimens of 6-week-old treated and control mice 
were dissected and fixed in 0.1 M PBS buffer (pH 7.4) supplemented with 0.4 % 
paraformaldehyde and 2 % glutaraldehyde. Polymerisation (using fresh Epon resin) was 
carried out at 60 ºC for 24 hours as described (Miosge et al., 1999). 
 
3.2.1.5 TUNEL assay 
 
A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was 
performed to quantify apoptotic podocytes. Paraffin sections of the kidney were stained 
with In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) according to the 
manufacturer’s instruction. Nephrin (Acris Antibodies, Herford, Germany, 1:50) was 
costained as a podocyte marker and Alexa Fluor® 555 goat anti-guinea pig IgG (H+L) 
(Invitrogen) was used as a secondary antibody. 
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3.2.2 Cytokines 
 
All cytokine levels in plasma samples obtained from mice or supernatant collected from 
in vitro cell stimulations were estimated using ELISA kits following the manufacturer’s 
instructions. 
CCL2/MCP-1 or IL-6 levels in samples were measured using a commercially available 
ELISA kit (BD Biosciences). Immuno 96 well solid plate (Nunc) was coated with 100 µl 
of capture antibody using coating buffer (Phosphate buffer, pH 6.5) and incubated 
overnight at 4 °C. The plate was washed 3 times with wash buffer (PBS with 0.05 % 
Tween 20) and was blocked using assay diluent (PBS with 10 % FCS) for further 1 hour 
at room temperature. After blocking the plate was washed 3 times and 100 µl of standard 
and diluted samples in assay diluent were added to respective well and incubated at 
room temperature for 2 hours. After washing 5 times with wash buffer, 100 µl of HRP-
Conjugated detection antibody (1:250 times diluted in assay diluent) was added and 
incubated at room temperature in the dark for 1 hour. Final washing step with 7 times 
was followed and 100 µl of TMB substrate solution (freshly prepared) was added and 
incubated for 20 to 30 minutes followed by addition of stop solution (2 N H2SO4) and 
absorbance was read at 450 nm within 10 minutes of stop solution addition. The 
absorbance in each sample was calculated using the equation of regression line 
generated with by plotting absorbance of different standards against their known 
concentrations. 
 
3.2.3 RNA analysis 
 
A small piece of kidney from each mouse was preserved in RNAlater reagent (QIAGEN, 
Hilden, Germany) and cells for in vitro study were collected with lysis buffer containing 
1 % of β-Mercaptoethanol using scraper and stored at -20 °C before RNA isolation. 
Total RNA was isolated from kidney or cells using an RNA extraction kit (QIAGEN) 
according to the manufacturer´s instructions. In brief, 20-30 mg of kidney stabilized in 
RNAlater reagent was disrupted in 600 µl of lysis buffer containing 1 % of β-
Mercaptoethanol using a conventional rotor-stator homogenizer for 30-40 seconds. The 
cleared lysate collected by centrifugation at 8000 rpm for 5 minutes was mixed with 
equal volume of 70 % ethanol. The sample mixture was transferred to a RNA column 
and centrifuged at 11,000 rpm for 15 seconds. After the lysate was washed with a half 
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volume of wash buffer I, DNase I mixed in buffer RDD (10 µl DNase I in 70 µl RDD, 
RNase free-DNase set, QIAGEN) was added and incubated at room temperature for 15 
minutes to remove DNase. Remained half volume of wash buffer I was added and 
further procedures were performed. The RNA was finally eluted in 32 µl of RNase-free 
water by centrifugation. 
The concentration of RNA was determined by measuring the absorbance at 260 nm in a 
spectrophotometer. RNA samples were diluted in DEPC water (2 µl of RNA + 98 µl of 
RNase-free water, 50 times dilution) and absorbance was measured at two wavelengths 
as 260 nm and 280 nm.  
 
Amount of RNA (µg/µl) = O.D. at 260 nm * 40 * 50 (dilution factor)/ 1000 
 
The ratio of optical densities at 260 nm and 280 nm is an indicator for RNA purity 
(indicative of protein contamination in the RNA samples). Only samples with a ratio of 
1.8 or more were considered to be of acceptable quality.  
By using NanoDrop spectrophotometer, 2 µl of RNA sample was used to detect its 
concentration indicating as ng/µl.   
The quality of isolated RNA was determined by agarose gel electrophoresis. RNA 
samples were mixed with RNA loading buffer containing ethidium bromide (Sigma-
Aldrich) and were heated at 65 °C for 10 minutes, then were loaded on the 1.5 % 
agarose gel. After running gel the RNA bands were visualized by UV light and 
documented. RNA samples showing a single bright band were considered to be of good 
quality. Loss of RNA integrity could be detected as smear formation in the agarose gel. 
 
3.2.4 cDNA synthesis and real-time RT-PCR (SYBR Green)  
 
After isolation of RNA, cDNA was synthesized using reverse transcripase (Superscript 
II; Invitrogen, Carlsbad, CA, USA). 1-2 µg of RNA samples were diluted in DEPC 
water and incubated at 65 °C for 5 minutes for denaturation. The RNA samples placed 
on ice were mixed with master mix1). The samples were incubated at 42 °C for 90 
minutes on thermal shaker and the reaction was stopped by heat-inactivation at 85 °C for 
5 minutes. 
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The synthesized cDNA samples were mixed with 2x SYBR Green master mix2), gene-
specific forward and reverse primer pair (each primer concentration is 10 pmol/µl), and 
Taq polymerase  
 
1) Master mix: 5x Fs buffer (Invitrogen), 25 mM dNTPs (Invitrogen), 0.1 M DTT 
(Invitrogen), RNasin (Promega, Mannheim, Germany), Hexanucleotide (Roche, Manheim, 
Germany), Superscript II (Invitrogen) or DEPC water in the case of the control cDNA (RT 
minus).  
 
2) 2x SYBR Green master mix: 10x Taq buffer without detergent (Fermentas, St. Leon-
Rot, Germany), dNTPs (Invitrogen), PCR Optimizer (Bitop, Berlin, Germany), BSA 
PCR grade (Fermentas), SYBR Green I (Fluka), 25 mM MgCl2 (Fermentas), and DEPC 
water. 
 
SYBR Green Dye detection system was used for quantitative real-time PCR on Light 
Cycler 480 (Roche) using 18s rRNA as a housekeeper gene. Gene-specific primers (300 
nM, Metabion, Martinsried, Germany) were used as listed in material part. Controls 
consisting of DEPC water were negative for target and housekeeper genes. To reduce the 
risk of false positive crossing point (Cp) the high confidence algorithm was used. The 
melting curves profiles were analyzed for every sample to detect eventual unspecific 
products or primer dimers.  
 
For RT-PCR following protocol was used. 
Pre-incubation was carried out for 5 minutes at 95 °C so as to activate the polymerase and 
complete de-naturation of cDNA samples. Followed by amplification for 40 cycles, each 
comprising of 15 seconds incubation at 95 °C and 45 seconds incubation at 60 °C. For 
melting curve initial 95 °C for 5 seconds followed by 65 °C for 1 minute with continuous 
heating was used. The RT-PCR for the reference genes (18S rRNA) was carried out under 
similar conditions. The Cp values were calculated using the Light Cycler480 and the 
results were normalized with respective reference gene expression for each sample. In all 
cases controls consisting of DEPC water were negative for target or reference genes. All 
designed SYBR green primers for all genes evaluated were obtained from Metabion 
(Martinsried, Germany). 
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3.2.5 Flow cytometry 
 
Renal cell suspensions were prepared and stained for flow cytometry using a 
FACScalibur machine as previously described (Vielhauer et al., 2003). In brief, kidneys 
were mechanically disrupted and incubated in 1x Hanks´balanced salt solution (HBSS) 
containing 1 mg/ml collagenase type I and 0.1 mg/ml deoxyribonuclease type I (Sigma-
Aldrich) for 20 minutes at 37°C. After washes tissues were incubated in 5 ml 2 mmol/L 
EDTA in 1x HBSS (without calcuim and magnecium) for 20 minutes at 37°C. The 
supernatant containing isolated cells was kept on ice and for a second enzyme step the 
remaining pellet was incubated in 5 ml of 1 mg/ml collagenase I in 1x HBSS for for 20 
minutes at 37°C. The suspension was subsequently passed through a 19-gauge, 27-gauge 
needle, and pooled with the first supernatant from the EDTA incubation. Cells were 
filtered through a 70-µm cell strainer (BD, Heidelberg, Germany) and washed twice in 
PBS. All washing steps were performed in FACS buffer (PBS containing 0.2 % of BSA 
and 0.1 % of NaAzide). Renal leukocytes were characterized by using the following 
antibodies: PE-conjugated anti-CD45 (clone 30-F11, BD), PE- or allophyocyanin-
conjugated anti-CD11b (clone M1/70, BD), FITC-conjugated anti-CD3ε (clone 145-
2C11, BD), anti-CD11c (clone N418, Serotec, Oxford, UK), anti-Ly6G (clone 1A8), 
anti-Ly6C (clone AL-21, BD), allophyocyanin-conjugated anti-CD4 (clone RM4-5, 
BD), F4/80 (clone CL:A3-1, Serotec, Oxford, UK), anti-Ly6G and C (clone RB6-8C5, 
BD), and PerCp-conjugated anti-CD8a (clone 53-6.7, BD). 
 
3.2.6 Isolation of renal macrophages 
 
In brief, kidneys were finely minced and digested for 30 minutes at 37°C with 1 mg/ml 
collagenase type I and 0.1 mg/ml deoxyribonuclease type I (Sigma-Aldrich) in HBSS. 
The digested tissues were washed and filtered through 30 µm nylon mesh filter to 
remove debris and cell segments. Renal CD11b+ macrophages were isolated using 
microbead-conjugated antibodies (Miltenyi Biotech, Bergisch-Gladbach, Germany). 
Magnetic bead separation was done according to the manufacturer’s instructions. 
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3.2.7 Protein isolation and Western blotting 
 
Protein from kidney tissues was extracted with lysis buffer (50 mM Tris HCL, 150 mM 
NaCl, 100 µM sodium ortovanadate, 0.5% sodium deoxycholate, 4 % NP 40, 2 % Triton 
X-100, 5 mM EDTA, 300 mM sucrose and protease inhibitors). After determination of 
protein concentrations, 50 µg of the protein was mixed with 5x SDS loading buffer (100 
mM Tris-HCl, 4% SDS, 20% glycerol, and 0.2% bromophenol blue) for Western blot 
analysis. Samples were heated at 95°C for 5 minutes. Proteins were separated by SDS 
PAGE and then transferred to a polyvinylidene difluoride membrane. Nonspecific 
binding to the membrane was blocked for 2 h at room temperature with 5% BSA in Tris-
buffered saline buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20). The 
membranes were then incubated overnight at 4°C with goat anti-mouse TNF-α (R&D 
systems) or rabbit anti-ß actin (Cell Signaling, Danvers, MA). After washing, the 
membrane was incubated with a peroxidase-conjugated donkey anti-goat IgG (Dianova, 
Hamburg, Germany) in Tris buffered saline buffer. The signals were visualized by an 
enhanced chemiluminescence system (Amersham, Bukinghamshire, UK). 
 
3.2.8 In vitro studies 
Isolation of renal interstitial fibroblasts 
 
Renal fibroblasts were prepared as previously described (Clayton et al., 1997). In brief, 
kidneys were harvested from 129/SvJ wild type mice. Minced kidneys were passed 
through cell strainers (70 and 30 µm) and incubated in normal cell culture medium at 37 
°C, 5 % CO2 for 1 to 2 hr to deplete monocytic cells or lymphocyte-like cells. The cells 
were cultured in Dublecco´s modified Eagle medium (DMEM) supplemented with 10 % 
fetal calf serum (FCS) and 1 % penicillin-streptomycin 100 U/ml and 100 µg/ml. After 
several passages until overgrowing of fibroblasts, positive selection of fibroblasts was 
isolated by magnetic cell sorting technique (MACS separation, Miltenyi Biotec, Bergish 
Gladbach, Germany). Cells were stained with primary PE-conjugated antibody 
(monoclonal anti-mouse CD90, Clone 30-H12, Acris Antibodies, Hiddenhausen, 
Germany) in 100 µl buffer containing PBS pH 7.2, 0.5 % BSA and 2 mM EDTA at 4 °C 
for 10 minutes in the dark. The cells were washed by adding 1-2 ml of buffer and 
centrifuged twice. Pellets were resuspended in buffer mixed with anti-PE microbeads 
and incubated at 4 °C for 15 minutes in the dark. The collection of labelded cells was 
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carried out by passing through MACS LS column.  After separation cells were 
characterized by FACS analysis. 
Cells were treated with either medium or various stimuli; Pam3CysSK4 (Invivogen, San 
Diego, CA), ultrapure LPS (Invivogen), CpG-ODN 1668 (TIB Molbiol, Berlin, 
Germany), and TNF-α (ImmunTools, Firesoythe, Germany). Total RNA and cell culture 
supernatants were harvested after 24 or 48 hours for real time RT-PCR and ELISA, 
respectively.  
 
Isolation of bone marrow-derived macrophages  
 
Bone marrow-derived macrophages were prepared from 129/SvJ wild type or col4a3-
deficient mice as described (Davies and Gordon, 2005; Zhang et al., 2008) with some 
modifications.  Bone marrow from tibia and femur was collected by flushing with 
DMEM and red blood cells were removed by incubating in 0.155 M NH4Cl. Washed 
cells were resuspended in 1x HBSS and cultured in DMEM supplemented with 10 % 
FCS, 1 % penicillin-streptomycin, and 5 ng/ml of M-CSF (ImmunoTools) or 20 % L929 
culture supernatant containing CSF at 37 °C, 5 % CO2. Every 2 day the medium was 
changed (Boltz-Nitulescu et al., 1987). After 6-7 days cells were used for stimulation. 
Macrophages were characterized by flow cytometry using fluorescently labeled 
antibodies (PE-conjugated anti-CD11b, allophyocyanin-conjugated anti-F4/80).  The 
subset of macrophages were identified by double positive population of CD11b and 
F4/80 and distinguished from other cell types by using FITC-conjugated anti-CD3 as a T 
cell marker, PE-conjugated anti-CD11c (clone HL3, BD Biosciences) as a dendritic cell 
marker, and allophyocyanin-conjugated anti-Ly6G/C as a granulocyte (neutrophils) 
marker. 
Cells were incubated with 2.5 % FCS contained-medium, LPS or CpG-DNA at various 
concentrations for 24 hours before harvesting total RNA or cell culture supernatants, 
respectively.  
 
3.2.6 Statistical analysis 
Paired Student`s t-test was used for the comparison of single groups. A value of p < 0.05 
was considered to indicate statistical significance. Survival curves were compared by 
Kaplan-Meier analysis by log-rank two-tailed testing. 
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4. Results 
4.1 Endogenous factors contributing to Alport nephropathy 
4.1.1 Leukocyte infiltration of Alport nephropathy in Col4a3-/- mice  
 
Alport disease is characterized by progressive glomerulosclerosis and subsequent 
progressive tubulointerstitial injury, leading to ESRD. In 6-week-old Col4a3-deficient 
mice, CD45+ leukocytes accumulate in the glomerular and in the tubulointerstitial 
compartment during the progression of Alport nephropathy (Figure 13).  
Hence, we first determined the leukocyte accumulation of Alport nephropathy during 
aging and then characterized the leukocyte subsets of kidney cell suspensions by flow 
cytometry (Figure 14A). The number of renal CD45+ leukocytes increased from 4-week 
-old Col4a3-deficient mice and the leukocytes were remarkably detected at 6 and 9 
weeks of age (Figure 14B). The leukocyte subsets in CD45+ gated cells were 
characterized by using additional surface markers. F4/80+/CD11c+ and F4/80-/CD11c+ 
dendritic cells as well as F4/80+/CD11c- macrophages were the largest leukocyte 
populations in kidneys of Col4a3-deficient mice. CD3+/CD4+ and CD4+/CD8+ T cells 
and Gr-1+/Ly6G+ neutrophils were also present in kidneys of Col4a3-deficient mice 
(Figure 14C). Thus, the progression of Alport nephropathy is associated with leukocytes 
infiltrates, especially of macrophages and dendritic cells. 
 
 
Figure 13.  Histopathology of Col4A3-deficient mice.  
Renal sections were obtained from 6-week-old wildtype and Col4a3-deficient mice and stained for CD45 
to identify infiltrating leukocytes. Representative images are shown and glomeruli are indicated by 
asterisks and CD45+ cells are indicated by arrows. Note that CD45+ cells infiltrate glomeruli and the 
interstitial compartment of Col4a3-deficient mice. Original magnification x200. 
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Figure 14.  Infiltrating leukocytes in murine Alport nephropathy.  
Renal cell suspensions were prepared for leukocyte flow cytometry from 4, 6, and 9-week-old wildtype 
and Col4a3-deficient mice as described in Methods. (A) Examples of flow cytometry dot plots to 
characterize individual CD45+ cell populations in total renal cell suspension. CD4+ T cells: 
CD45+/CD3+/CD4+/CD8-, CD8+ T cells: CD45+/CD3+/CD4-/CD8+, Neutrophils: CD45+/Ly6G+/Gr-
1+, F4/80+ DCs: CD45+/CD11c+/F4/80+, F4/80-DCs: CD45+/CD11c+/F4/80-, Macrophages: 
CD45+/CD11c-/F4/80+. (B) The proportion of CD45+ cell population in total renal cells from 4, 6, and 9 
week-old wildtype and Col4a3-deficient mice. (C) Intrarenal leukocyte subsets were characterized by 
additional surface markers as described. Data represent the percentage of all kidney cells ± SEM from 5-7 
mice in each group. * p<0.05, ** p<0.01, *** p<0.001 versus wildtype mice. 
 
 
4.1.2 TNF-α expression in Col4a3-/- mice with Alport nephropathy 
 
The increased leukocyte influx indicates the presence of tissue injury and inflammation 
in many of progressive kidney diseases and progressive inflammatory responses result 
in a massive proinflammatory cytokine/chemokine production such as IL-6, 
CCL2/MCP-1, and TNF-α. TNF-α has inflammatory and apoptotic functions 
(Varfolomeev and Ashkenazi, 2004), and it is a candidate protein that may be involved 
in the regulation of renal parenchymal cells, e.g. podocyte. Whether TNF-α is at all 
expressed during the progression of ‘non-inflammatory’ types of glomerulosclerosis is 
not known, hence, a functional role of TNF-α for the progression of diseases like Alport 
nephropathy is at all speculative. We therefore first studied the mRNA and protein 
expression of TNF-α throughout the progression of Alport nephropathy in Col4a3-
deficient mice. 
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To address the expression of TNF-α in Alport nephropathy, we first quantified TNF-α 
mRNA expression levels in total kidney mRNA on different ages (4, 6, and 9 week) of 
wildtype (Col4a3+/+) and Col4a3-deficient mice. While TNF-α mRNA was hardly 
detectable in wildtype kidneys, Col4a3-deficient kidneys significantly upregulated TNF-
α mRNA expression (Figure 15A). Western blot confirmed the induction of intrarenal 
TNF-α at the protein level (Figure 15B). Next we performed immunostaining in order to 
observe the localization of intrarenal TNF-α expression in 9-week-old Col4a3-deficient 
mice. Staining intensity was most prominent in the glomerular compartment where the 
predominant TNF-positivity was localized to the mesangium as well as to podocytes 
(Figure 15C). Together, TNF-α is increasingly expressed during the progression of 
Alport nephropathy of Col4a3-deficient mice, e.g. in glomerular cells including 
podocytes.  
 
4.1.3 TNF-α expression in intrarenal leukocytes of Col4a3-/- mice 
 
Leukocytes have been described as an important source of intrarenal TNF-α expression 
in other types of kidney diseases (Vielhauer and Mayadas, 2007). To address this issue 
in Alport nephropathy, we analyzed renal cell suspensions of Col4a3-deficient mice by 
multicolour flow cytometry. The number of intrarenal CD45+ leukocytes was markedly 
elevated from 6 weeks of age and did not increase any further up to 9 weeks of age 
(Figure 14B). On flow cytometery an increased number of TNF-α expressing cells was 
positive for mostly CD45+ leukocytes in total kidney cell suspension from Col4a3-
deficient mice as compared to less percent in wild-type mice (Figure 16A) which had 
much intrarenal leukocyte numbers (Figure 14B). Additional surface staining data 
indicates that CD45+TNF-α+ cells from Col4a3-deficient mice was present in all 
leukocyte subsets including T cells, neutrophils, CD11+ dendritic cells and renal 
macrophages as compared to age-matched wildtype mice (Figure 16B). Together, 
Alport nephropathy is associated with intrarenal TNF-α expression which originates 
from renal parenchymal cells, e.g. podocytes, as well as from infiltrating immune cells.  
   55 
 
Figure 15. TNF-α expression in murine Alport nephropathy. (A) TNF-α mRNA levels were quantified 
by real time RT-PCR from renal samples of 4, 6, and 9-week-old wildtype and Col4a3-deficient mice as 
indicated. Data are mean ratios ± SEM to the respective 18s rRNA. (B) TNF-α protein expression was 
determined by Western blot on renal protein extracts from 9-week-old wildtype and Col4a3-deficient 
mice, accordingly. Respective β-actin stains are shown as loading control. (C) TNF-α immunostaining in 
kidneys of wildtype and Col4a3-deficient mice illustrated positive staining signals in glomeruli (white 
arrows in the upper panel, original magnification x100). At higher magnification (lower panel, original 
magnification x1000) TNF-α positivity localizes to the mesangium and to podocytes in Col4a3-deficient 
mice only.  
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Figure 16. TNF-α-secreting leukocytes in murine Alport nephropathy. Renal leukocytes were 
identified by flow cytometry for CD45 in kidney cell suspensions of 4, 6, and 9-week-old wildtype and 
Col4a3-deficient mice. (A) Intracellular staining for TNF-α was used to quantify the amount of TNF-α-
producing leukocytes. (B) Leukocyte subsets were characterized by additional surface markers. Data 
represent the percentage of means ± SEM from 5-7 mice in each group. *** p<0.001 wildtype versus 
Col4a3-deficient mice. 
 
4.1.4 TNF-α blockade prolongs life span of Col4a3-/- mice 
 
Given the renal TNF-α expression during the progression of Alport nephropathy, we 
questioned whether TNF-α itself contributes to renal pathology and renal failure. To 
address this issue, we randomized 4-week-old Col4a3-deficient mice into three groups 
that either received injections of saline, of 100 µg etanercept or 100 µg of human IgG for 
a period of five weeks. The latter group served as a control group because etanercept is a 
TNF-α antagonist that consists of a TNFR binding domain linked to the Fc part of 
human IgG1. The dose of etanercept was chosen by additional experiments with two 
groups: low dose (50µg) for 5 weeks and same dose (100µg) for 3 weeks. Finally, best 
dose and period for longest prolonged life span was selected (data not shown). In a first 
experiment, all groups were followed to monitor overall survival, which serves as a 
robust readout parameter for ESRD and uremic death in this model. Etanercept treatment 
significantly prolonged life span by two weeks, i.e. 20% of total life span of Col4a3-
deficient mice as documented by a mean survival of 81 days versus 68 days in IgG- or 
untreated Col4a3-deficient mice (Figure 17). Thus, TNF-α blockade with etanercept 
from 4 weeks of age prolongs the life span of Col4a3-deficient mice. 
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Figure 17. TNF blockade and life span of Col4a3-deficient mice. 4-week-old Col4a3-deficient mice 
were received either saline, human IgG or etanercept injections for 5 weeks. Survival time is illustrated as 
Kaplan-Meier curve. Mean survivial is indicated for vehicle and etanercept groups.  
  
4.1.5 TNF-α blockade improves renal function in Col4a3-/- mice  
 
To test whether the effect of etanercept on overall survival relates to its effect on renal 
function, we measured GFR as a marker of the kidney´s excretory function at the age of 
4, 6, and 8 weeks in mice of all groups. GFR measurements after 2 and 4 weeks of 
treatment revealed a progressive decline of renal function in untreated Col4a3-deficient 
mice, while TNF-α blockade with etanercept significantly improved GFR compared to 
their untreated Col4a3-deficient mice controls, albeit not reaching the level of wildtype 
mice (Figure 18A). Consistent with this finding, the progressive increase of plasma 
creatinine and BUN levels seen in untreated Col4a3-deficient mice were significantly 
reduced by etanercept treatment (Figures 18B and 18C). Proteinuria, a marker of renal 
barrier function, was determined as urinary albumin-creatinine ratio (UACR). There was 
a trend towards lower UACR in etanercept treated mice which, however, did not reach 
statistical significance (Figure 18D). Together, TNF-α blockade with etanercept, 
prolongs life span of Col4a3-deficient mice in association with improved excretory renal 
function.  
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Figure 18. TNF-α blockade and renal function of Col4a3-deficient mice. (A) GFR was determined as a 
functional marker of the glomerular filtration barrier at week 4, 6, and 8 weeks in mice of all groups. Note 
that etanercept treatment significantly increaseed GFR as compared to saline-treated Col4a3-deficient 
mice. Plasma creatinine (B), blood urea nitrogen (C), and urinary albumin/creatinine ratios (D) were also 
determined throughout the study as indicated. Data represent means ± SEM,  * p<0.05, *** p<0.001. 
 
4.1.6 TNF-α blockade protects Col4a3-/- mice from glomerulosclerosis  
 
Does the effect of etanercept on the life span and renal function of Col4a3-deficient 
mice relate to renal pathology? To answer this question, we treated a second cohort of 
mice and performed a cross sectional analysis of all groups at 9 weeks of age. Renal 
sections from mice of all groups were stained with Periodic acid-Schiff stain (PAS) and 
the extent of glomerulosclerosis was quantified by a semiquantitative sclerosis score 
ranging from 0 to 4, describing sclerosis in 0, 1-25%, 26-50%, 51-75%, and 76-100% of 
glomeruli, respectively. 9-week-old Col4a3-deficient mice displayed a significant 
percentage of glomeruli with scores 3 and 4 indicating severe diffuse glomerulosclerosis. 
TNF-α blockade with etanercept significantly reduced the percentages of glomeruli with 
a sclerosis score of 3 or 4 and increased those with a score of 1 and 2 indicating a shift 
towards less severe glomerular lesions (Figure 19). At the ultrastructural level the 
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characteristic abnormalities of Alport nephropathy, i.e. GBM irregularities, podocyte 
foot process effacement, and massive increase of mesangial matrix became evident in 
Col4a3-deficient mice. Many glomeruli were affected by extracapillary cell proliferation 
in areas of podocyte denudation (Figure 20). Etanercept treatment did not affect the 
GBM irregularities, podocyte foot process effacement, and increase of mesangial matrix 
but sclerotic or extracapillary proliferative lesions were far less common. Together, 
TNF-α blockade with etanercept protects Col4a3-deficient mice from diffuse 
glomerulosclerosis as a manifestation of advanced Alport nephropathy. 
 
 
Figure 19. TNF-α blockade and renal histopathology in of Col4a3-deficient mice. (A) Renal sections 
of 9-week-old mice from all groups were stained with periodic acid Schiff solution. The figure includes 
representative images of single glomeruli from mice of all groups as indicated, original magnification 
x400. (B) The extent of glomerulosclerosis was evaluated in mice of all groups by using a 
semiquantitative sclerosis score ranging from 0 (no sclerosis) to 4 (global sclerosis) as described in the 
Methods part. Data represent means ± SEM. * p<0.01, # p<0.001 saline- versus etanercept-treated Col4a3-
deficient mice.  
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Figure 20. Glomerular ultrastructure in 9-week-old Col4a3-deficient mice. The glomerular 
ultrastructure was assessed by transmission electron microscopy in 9-week-old wildtype and Col4a3-
deficient mice as indicated. Note that lack of Col4a3 is associated with irregular GBM thickness and 
podocyte foot process effacement as compared to age-matched wild-type mice. In addition, collapse of 
glomerular capillaries and diffuse glomerular matrix expansion indicates advanced glomerulosclerosis. 
Etanercept treatment reduced glomerular scarring but did not affect the GBM abnormalities and podocyte 
foot process effacement as noted at high magnification. 
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4.1.7 TNF-α blockade prevents podocyte loss in Col4a3-/- mice 
 
Podocyte loss is the central pathomechanism that drives the progression of glomerular 
diseases towards diffuse glomerulosclerosis (Kriz and Lemley, 1999; Wharram et al., 
2005). Therefore, we questioned whether the progression of Alport nephropathy in 
Col4a3-deficient mice is associated with quantifiable podocyte loss and whether the 
protective effect of etanercept is associated with increases podocyte numbers. We first 
used WT-1 immunostaining to quantify glomerular podocytes, a method that has been 
successfully used in other disease models such as diabetic nephropathy db/db mice. 
However, we found faint WT-1 positivity also in parietal epithelial cells of mildly 
affected glomeruli and strong positivity of overgrowing parietal epithelial cells in 
severely sclerotic glomeruli which did not allow a reliable quantitative assessment of 
glomerular podocyte numbers (not shown). We therefore used double 
immunofluorescence for WT-1 and nephrin to identify and quantify glomerular 
podocytes. Figure 21A illustrates podocytes as nephrin-WT-1 positive cells at their 
typical location in wild-type mice. In 9-week-old Col4a3-deficient mice such nephrin-
WT-1 positive podocytes were less frequent and large sclerotic parts of many glomeruli 
were overgrown by nephrin negative cells (Figures 21B and 21C). Occasionally, nephrin 
and WT-1 positive intratubular casts were seen, indicating that detached podocytes can 
become a component of cellular casts (Figure 21D). TNF-α blockade with etanercept 
significantly increased the numbers of nephrin/WT-1 positive podocytes in that ways 
that focal sclerosis was far more common as globally sclerotic glomeruli (Figures 21E 
and 21F). Next we quantified TUNEL/nephrin positive cells in glomeruli to assess 
asapoptotic podocytes. Alport nephropathy was associated with the occurrence of 
TUNEL positive podocytes which could not be detected in age-matched wildtype control 
mice (Figure 22). Etanercept treatment significantly reduced the numbers of 
TUNEL/nephrin positive glomerular cells (Figure 22), indicating that etanercept 
protected from Alport mice from podocyte apoptosis. Analyzing renal mRNA expression 
profiles of nephrin and podocin confirmed that TNF-α blockade with etanercept had a 
podocyte-protective effect as untreated Col4a3-deficient mice had decreased expression 
levels of podocyte markers which were prevented by TNF-α blockade (Figure 23A). By 
contrast, the mRNA expression levels of proinflammatory genes such as IL-6, CCL2, 
CCL5, and TNF-α itself were not significantly reduced with TNF-α blockade (Figure 
23A). Accordingly, etanercept treatment did not affect renal leukocyte counts in Col4a3-
deficient mice at the end of the study (Figure 23B). Thereby it limits an essential 
downstream pathomechanism for progressive glomerulosclerosis of Col4a3-deficient 
mice with Alport nephropathy.  
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Figure 21. Podocytes in Col4a3-deficient mice. WT-1/nephrin costaining was used to quantify 
differentiated podocytes in kidneys of 9-week-old mice from all groups. (A) Note nuclear WT-1 and 
cytoplasmatic nephrin double positive podocytes in a normal glomerulus of a wildtype mouse. Faint WT-1 
staining is occasionally observed parietal epithelial cells. (B) Age-matched Col4a3-deficient mice display 
a different glomerular staining pattern with only few WT-1/nephrin double positive cells and predominant 
WT-1+/nephrin- cells (encircled). (C) This image ilustrates that these WT-1+/nephrin- cells overgrow the 
glomeruli in a crescent-like fashion. (D) WT-1/nephrin double positive cells form intratubular casts (white 
arrows) indicating that podocyte detachment from the GBM, i.e. podocyte loss. (E) TNF-α blockade with 
etanercept partially restored normal glomerular architecture and only segmental loss of WT-1/nephrin 
double positive podocytes (encircled). (F) Quantitative analysis of lead to WT-1/nephrin double positive 
differentiated podocytes in 9-week-old mice from all groups. Data represent means ± SEM.  
 
 
 
 
 - 
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Figure 22. TUNEL+podocytes in Col4a3-deficient mice. TUNEL/nephrin costaining was used to 
quantify apoptotic podocytes in kidneys of 9-week-old mice of all groups in 50 glomeruli per mouse 
section. TUNEL staining (green) identified apoptotic renal cells, and red staining identified nephrin-
positive podocytes. (A) wildtype, (B) saline-treated Col4a3-deficient mice, (C) etanercept-treated  Col4a3-
deficient mice, (D) quantitative analysis of lead to nephrin/TUNEL double positive apoptotic podocytes. 
Data represent means ± SEM.  
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Figure 23. Renal mRNA expression and leukocyte counts in Col4a3-deficient mice. (A) Total kidney 
mRNA was prepared from mice of all groups for real-time RT-PCR. Renal mRNA expression levels were 
calculated as ratio per respective 18s rRNA expression. Data represent means ± SEM from 6-8 mice. (B) 
Renal leukocytes were quantified by flow cytometry in kidney cell suspensions of 9-week-old Col4a3-
deficient mice as described in methods. Data represent the percentage of all kidney cells ± SEM from 5-7 
mice in each group. Note that TNF-α blockade with etanercept did not affect any leukocyte subset. * 
p<0.05 saline- versus etanercept-treated Col4a3-deficient mice. 
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4.2 Exogenous factors that accelerate the progression of Alport nephropathy 
4.2.1 Effect of innate immunity on renal parenchymal cells  
 
Numerous factors such as toxic, metabolic, infectious or traumatic types may be 
involved in pathomechanisms that aggrevate progressive renal disease. For example, 
intrinsic renal cells including mesangial cells, endothelial cells, tubular epithelial cells, 
and podocytes express several types of TLRs and these cells by TLR activation are 
sufficient to release proinflammatory cytokines and chemokines aggrevating renal injury 
(Anders, 2007). We speculated that TLR activation of intrinsic renal cells in response to 
PAMP-like molecules such as LPS, lipopeptides or bacterial DNA also triggered the 
secretion of proinflammatory and profibrotic mediators.  
To address this issue, we isolated CD90+ renal fibroblasts from 6-week-old mice and 
stimulated them with agonists for TLR2 (Pam3Cys lipopetide), TLR4 (LPS), TLR9 
(CpG-DNA) and with TNF-α. TLR2 and TLR4 stimulation activated renal fibroblasts 
and induced IL-6 and CCL2/MCP-1 mRNA expression (Figure 24A), while TGF-β, 
collagen-1α, and smooth muscle actin expression remained unchanged (Figure 24B). 
The CpG-DNA had no significant effect on CCL2/MCP-1 mRNA expression because 
renal fibroblasts do not express TLR9 (data not shown). Finally, the protein levels of 
CCL2/MCP-1 and TGF-β as detected by ELISA in collected supernatant from renal 
fibroblast cultures was also shown to remain unchanged (Figure 24C). Thus, TLR 
activation in renal fibroblasts triggers proinflammatory mediators, like CCL2/MCP-1 
and IL-6, but does not induce the production of profibrotic molecules like TGF-β, 
collagen-1α, and smooth muscle actin in renal fibroblasts.   
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Figure 24. TLR-induced expression of cytokines and profibrotic mediators in renal fibroblasts. 
CD90+ fibroblasts were prepared from mice and cultured as described in methods. The cells were 
stimulated with either Pam3Cys lipopetide (TLR2 agonist), LPS (TLR4 agonist), CpG-DNA (TLR9 
agonist) or TNFα. (A), (B) After 24 h cells were harvested and the mRNA expression was quantified by 
real-time PCR and normalized to the 18S rRNA level. (C) Cell culture supernatants were obtained after 
48h stimulation. MCP-1 and TGF-β levels were measured by ELISA. Data represent means ± SD from 
three independent experiments. * p<0.05 versus medium.  
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4.2.2 Macrophage activation via TLRs in Alport nephropathy 
 
Glomerulosclerosis is a major cause of ESRD in patients with Alport nephropathy, albeit 
tubulointerstitial fibrosis with interstitial leukocytes also contributes to the disease 
progression. As described above, leukocyte cell infiltration is associated with disease 
progression. Previous studies with Col4a3-deficient mice show that the blockade of 
chemokine receptor CCR1 reduces renal fibrosis and prolonged life span, whereas the 
blockade of CCL2/MCP-1 has no effect (Clauss et al., 2009; Ninichuk et al., 2005). 
Macrophages in Alport kidneys might therefore have a non-inflammatory phenotype by 
displaying low expression of CCR2. In fact, the phenotype or activation state of renal 
macrophages is thought to significantly affect the extent of renal inflammation and tissue 
damage (Ricardo et al., 2008). M1 macrophage infusion aggravated renal damage and 
dysfunction, whereas M2 macrophage infusion reduced renal pathology and improved 
renal function (Anders et al., 2003a; Anders et al., 2003b; Huang et al., 2000; Wang et 
al., 2007).  
Therefore, we hypothesized that the activation state of renal macrophages would affect 
disease progression of Alport nephropathy in Col4a3-deficient mice. We speculated that 
classically-activated macrophages by e.g. TLR activation would increase renal 
inflammation and accelerate the progression of Alport nephropathy. To address this 
issue, we induced TLR activation with TLR agonists in Col4a3-deficient mice. Mice 
received a series of injections with LPS or with unmethylated CpG-ODNs. CpG-DNA 
was selected because it mimicks the potential of bacterial DNA to selectively activate 
macrophages and dendritic cells via TLR9 (Anders, 2007). LPS mimicks infection with 
Gram-negative bacteria and activates macrophages via TLR4. With this study design, we 
also addressed the question whether infections affect the progression of Alport 
nephropathy, e.g. by modulating intrarenal inflammation.  
 
4.2.2.1 Effect of LPS or CpG-DNA on life span of Col4a3-/- mice 
  
CpG-DNA and LPS are known triggers of leukocyte activation. CpG-DNA activates 
murine B cells, macrophages, and dendritic cells via the endosomal TLR9/MyD88 
signaling pathway (Hemmi et al., 2000). By contrast, LPS stimulates leukocytes as well 
as non-immune cells via TLR4, which in turn activates MyD88 and 
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Figure 25.  Plasma cytokine levels in Col4a3-deficient mice. Plasma cytokine levels of interleukin (IL)-
6 and CCL2/MCP-1) from 4-week-old wildtype and Col4a3-deficient mice treated with saline, LPS or 
CpG-DNA. Before and after 6 h of injection, plasma was obtained and cytokines were measured by 
ELISA. (A) IL6 and (B) CCL2/MCP-1 levels in 4-week-old of Col4a3-deficient mice injected with 10 µg 
of LPS and 40 µg of CpG-DNA as indicated.  Data represent as ± SEM from 4-6 mice in each group.  
 
TRIF signaling (Poltorak et al., 1998). Col4a3-deficient and wildtype mice received 
seven injections of CpG-DNA or LPS on alternate days starting from 4 weeks of age at a 
dose of 40 µg or 10 µg, respectively. These doses were selected because they induced 
similar plasma levels of IL-6 and CCL2/MCP-1 at 6 hours after single injection into 4-
week-old Col4a3-deficient mice (Figure 25). Studies of the mice until death revealed 
that CpG-DNA significantly reduced the life span of Col4a3-deficient mice as 
documented by a mean survival of 46 days versus 76 days in saline-treated Col4a3-
deficient mice (Figure 26). By contrast, LPS had no effect on the survival of Col4a3-
deficient mice. In addition, CpG-DNA or LPS injections did not affect the survival in 
wildtype mice until 150 days of age. Thus, systemic exposure to CpG-DNA, but not to 
LPS, shortens the life span of Col4a3-deficient mice. 
 
4.2.2.2 CpG-DNA, but not LPS, aggravates Alport nephropathy  
 
Does the effect of CpG-DNA on the life span of Col4a3-deficient mice cause 
acceleration of Alport nephropathy? To answer this question, we treated a second cohort 
of mice and performed a cross-sectional analysis of all groups at 6 weeks of age. Renal 
sections from mice of all groups were stained with PAS and the extent of 
glomerulosclerosis was quantified by a semiquantitative sclerosis score ranging from 0 
to 4 as described in the Methods section. In Col4a3-deficient mice, CpG-DNA 
A                                                       B 
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significantly increased the percentages of glomeruli with a sclerosis score of 3 or 4 and 
reduced those with a score of 0 and 2 indicating a shift towards more severe glomerular 
lesions (Figure 27). This was associated with a significant reduction in the number of 
podocytes per glomerulus (Figure 28). By contrast, LPS did not affect the 
aforementioned glomerular abnormalities in Col4a3-deficient mice (Figure 27 and 28). 
Neither CpG-DNA nor LPS injections affected the normal glomerular structure in 
wildtype mice (Figure 27). At the ultrastructural level the characteristic abnormalities of 
Alport nephropathy, i.e. GBM irregularities and podocyte foot process effacement 
became evident in Col4a3-deficient mice (Figure 29A). Additionally, extensive 
accumulation of extracellular matrix and podocyte damage was seen in in CpG-DNA-
injected Col4a3-deficient mice (Figure 29B). By contrast, LPS caused activation of 
glomerular endothelial cells as illustrated by luminal tubular extensions of endothelial 
cells (Figure 29B). Silver staining sections also showed the severe glomerular lesion by 
CpG-DNA (Figure 30). These morphological changes were associated with an increase 
of albuminuria and blood urea nictrogen levels in CpG-DNA treated Col4a3-deficient 
mice (Figure 31). Taken together, the effects of CpG-DNA on life span are associated 
with an acceleration of Alport nephropathy. 
 
 
Figure 26.  Life span of Col4a3-deficient mice. Wildtype and Col4a3-deficient mice were treated with 
saline, LPS or CpG-DNA from week 4 to 6 of age as indicated. Survival time is illustrated as Kaplan-
Meier curve.  
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Figure 27. Renal histopathology in 6-week-old wildtype and Col4a3-deficient mice. (A) Renal sections 
of wild-type and Col4a3-deficient mice were stained with periodic acid Schiff solution (B) The extent of 
glomerulosclerosis was evaluated in mice of all groups by using a semiquantitative sclerosis score ranging 
from 0 (no sclerosis) to 4 (global sclerosis) as described in the Methods part. Data represent means ± 
SEM. † p<0.05/‡ p<0.01 versus saline-treated mice of the same genotype. Data represent means ± SEM, * 
p<0.05 versus wildtype, † p<0.05 versus saline-treated mice of the same genotype. The figure includes 
representative images of single glomeruli from mice of all groups as indicated, original magnification 
x400. 
A 
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Figure 28. Renal histopathology in 6-week-old wildtype and Col4a3-deficient mice. (A) Renal sections 
of wild-type and Col4a3-deficient mice were stained with anti-WT-1. (B) The number of glomerular 
podocytes was quantified by counting WT-1+ cells in 15 glomeruli per section. Data represent means ± 
SEM, * p<0.05 versus wildtype, † p<0.05 versus saline-treated mice of the same genotype. The figure 
includes representative images of single glomeruli from mice of all groups as indicated, original 
magnification x400. 
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Figure 29. Glomerular ultrastructure in 6-week-old Col4a3-deficient mice. Electron microscopy was 
applied to assess the glomerular ultrastructure of 6-week-old wild-type and Col4a3-deficient mice. (A) 
Note that lack of Col4a3 is associated with irregular GBM thickness (►) and podocyte foot process 
effacement (⌂) as compared to age-matched wild-type mice (original magnification x25000). (B) At lower 
magnification (x3150) changes in glomerular matrix and capillary structure between wild-type and 
Col4a3-deficient mice become visible. Note that exposure of Col4a3-deficient mice to CpG-DNA caused 
extensive accumulation of extracellular matrix (*) with major capillary and podocyte abnormalities, i.e. 
glomerulosclerosis. By contrast, LPS exposure caused activation of glomerular endothelial cells, evident 
by tubular extensions into the capillary lumen (►). 
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Figure 30.  Renal lesion in Col4a3-deficient mice. Renal sections of wild-type and Col4a3-deficient 
mice were stained with silver. Images illustrate representative sections of kidneys from the respective 
groups at week 6 of age (original magnification 100x).  
 
 
 
 
 
Figure 31. Proteinuria and blood urea nitrogen in wildtype and Col4a3-deficient mice. Proteinuria 
(A) and blood urea nitrogen (B) were determined from 6-week-old of wildtype and Col4a3-deficient mice 
from all groups and calculated as described in Methods.  Data represent means ± SEM. * p < 0.05 versus 
wildtype mice. 
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4.2.2.3 CpG-DNA increases activated renal macrophages in Col4a3-/- mice  
 
Among those cells that infiltrate the kidney in Alport nephropathy, only macrophages 
and dendritic cells express TLR9 (Hemmi et al., 2000). Hence, we speculated that CpG-
DNA injections may aggravate Alport nephropathy by altering the numbers of 
leukocytes in kidneys of Col4a3-deficient mice. To address this issue, we performed 
quantitative flow cytometry of renal cell suspensions from mice of all groups at 6 weeks 
of age. CpG-DNA significantly increased the amount of renal F4/80+/CD11c- 
macrophages (and CD8+ T cells) but not those of renal CD11c+ dendritic cells in 
Col4a3-deficient mice (Figure 32). This was consistent with increased numbers of 
interstitial F4/80+ cells as well as Mac2+ glomerular macrophages in renal sections of 
Col4a3-deficient mice as determined by immunostaining (Figure 33). By contrast, LPS 
injections did not affect renal leukocyte numbers in Col4a3-deficient mice (Figures 32 
and 33). Similarly, neither CpG-DNA nor LPS injection affected the numbers of renal 
leukocytes in wildtype mice (data not shown). Next, we asked whether CpG-DNA 
injections also affected the functional phenotype of intrarenal macrophages. We 
addressed this question in various ways. We used, for example, flow cytometry to 
quantify the numbers of Ly6Chi intrarenal macrophages, which represent a classically-
activated proinflammatory (M1) phenotype (Mantovani et al., 2005; Mosser and 
Edwards, 2008). CpG-DNA injections significantly increased the numbers of intrarenal 
Ly6Chi positive macrophages as compared to LPS- or saline-treated Col4a3-deficient 
mice (Figure 32B). In summary, CpG-DNA accelerates kidney disease in Col4a3-
deficient mice in assocation with increased numbers of classically-activated renal 
macrophages. 
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Figure 32. CpG-DNA alters renal leukocyte infiltration in 6-week-old Col4a3-deficient mice. (A) 
Renal cell suspensions were prepared for leukocyte flow cytometry from 6-week-old wildtype and 
Col4a3-deficient mice in all groups. The marker CD11c+ identified DCs, macrophages were 
F4/80+/CD11c-. Data represent the percentage of all kidney cells ± SEM from 5-7 mice in each group. 
*p<0.05, **p<0.01, ***p<0.001, LPS- or CpG-DNA- versus saline-treated Col4a3-deficient mice. (B) 
The percentage of Ly6Chigh cells gated on CD11b+ population in kidney. * p<0.05 CpG-DNA versus all 
groups. 
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Figure 33. Immunostaining of renal sections. Renal sections of wild-type and Col4a3-deficient mice 
were stained with appropriate antibodies as indicated. The figure includes representative images of mice 
from all groups, original magnification x200 or x400. 
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4.2.2.4 CpG-DNA and LPS modulate the expression of macrophage markers  
 
In an alternative approach to characterize macrophage polarization we quantified a 
number of macrophage activation markers by real-time PCR using renal RNA extracts 
from mice of all treatment groups. All primers for macrophage phenotypes were 
previously tested using bone marrow-derived macrophages stimulated with different 
TLR agonists (data not shown). In Col4a3-deficient mice, CpG-DNA injection increased 
renal mRNA levels of the following M1 (classically-activated) macrophage markers: 
TNF-α, iNOS, IL-12, CXCL10 (Figure 34A). All of these markers were down-regulated 
in LPS -treated Col4a3-deficient mice. CpG-DNA injections also induced some of the 
markers that refer to M2 (alternatively-activated) macrophage such as arginine-1, TGF-
β, and Fizz-1 (Figure 34B). All aforementioned results were confirmed by real-time PCR 
analysis of mRNA isolates from CD11b+ cells that we isolated by magnetic beads from 
mice of all groups (Figure 35). The predominant intrarenal induction of TNF-α and 
iNOS mRNA by CpG-DNA was consistent with an increased glomerular (and 
interstitial) staining intensity by anti-iNOS IgG and anti-TNF IgG on renal sections of 
CpG-DNA- but not of saline- or LPS- treated Col4a3-deficient mice (Figure 33). 
Interestingly, TNF-α immunostaining was also positive on glomerular podocytes (Figure 
33). Taken together, mRNA profiling and immunostaining support that CpG-DNA 
accelerates kidney disease in Col4a3-deficient mice by modulating the phenotype of 
renal macrophages. 
 
4.2.2.5 Effect of CpG-DNA on Alport nephropathy is mediated by TNF-α  
 
Because the effects of CpG-DNA on kidney disease in Col4a3-deficient mice were 
associated with a marked induction of TNF-α, we questioned whether this accounts for 
the aggravation of Alport nephropathy. Thus, we treated additional Col4a3-deficient 
mice with CpG-DNA together with or without the TNF-α antagonist etanercept. 
Etanercept completely abrogated the effect of CpG-DNA on the acceleration of 
glomerulosclerosis as glomerular sclerosis scores were similar or even lower as 
compared to saline-treated Col4a3-deficient mice (Figures 36A and B). Similarly, 
etanercept significantly increased the numbers of WT-1+ podocytes in glomerular tufts 
(Figures 36C and D) and significantly reduced the albumin-creatinine ratio in CpG-
DNA-treated Col4a3-deficient mice (Figure 37A). The premature mortality of CpG-
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DNA-treated Col4a3-deficient mice was also improved from a mean letality at 46 days 
to 77 days by etanercept-treatment which was identical to saline-treated Col4a3-
deficient mice (Figure 37B). Thus, CpG-DNA accelerates Alport nephropathy in 
Col4a3-deficient mice via activating renal macrophages to secrete TNF-α. 
 
 
 
 
 
 
Figure 34. Renal mRNA expression of macrophage phenotype markers in Col4a3-deficient mice. 
Total kidney mRNA was prepared from mice of all groups for real-time RT-PCR. Markers of M1 (A) or 
M2 (B) macrophages were quantified and were calculated as ratio per respective 18s rRNA expression. 
The graph shows the mRNA levels of LPS- (white bars) or CpG-DNA-injected mice (black bars) relative 
to the levels of saline-treated mice to indicate induction or suppression of each marker.  
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Figure 35. mRNA profile of renal CD11b+ macrophage in Col4a3-deficient mice. mRNA of CD11b+ 
cells isolated from kidney of all groups was prepared for real-time RT-PCR. Markers of M1 (A) or M2 (B) 
macrophages were quantified and were calculated as ratio per respective 18s rRNA expression. The graph 
shows the mRNA levels of LPS- (white bars) or CpG-DNA-injected mice (black bars) relative to the 
levels of saline-treated mice to indicate induction or suppression of each marker.  
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Figure 36. Effect of TNF-α blockade with etanercept on CpG-DNA-induced aggravation of Alport 
nephropathy. (A) The extent of glomerulosclerosis was evaluated in mice of all groups by using a 
semiquantitative sclerosis score ranging from 0 (no sclerosis) to 4 (global sclerosis) as described in the 
Methods part. Data represent means ± SEM. † p<0.05 versus saline-/‡ p<0.05 versus CpG-DNA-treated 
Col4a3-deficient mice. (B) Renal sections of Col4a3-deficient mice were stained with periodic acid Schiff 
solution. The figure illustrates representative images of single glomeruli from mice of all groups as 
indicated, original magnification x400. (C) The number of glomerular podocytes was quantified by 
counting WT-1+ cells in 15 glomeruli per section. Data represent means ± SEM, † p<0.05 versus CpG-
DNA-treated Col4a3-deficient mice. (D) Renal sections of Col4a3-deficient mice were stained with anti-
WT-1. The figure illustrates representative images of single glomeruli from mice of all groups as 
indicated, original magnification x400. 
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Figure 37. Effect of TNF-α blockade on proteinuria and life span of CpG-DNA-accelerated Alport 
nephropathy. (A) Proteinuria was determined in 6-week-old wildtype and Col4a3-deficient mice the 
latter being treated either with CpG-DNA only or CpG-DNA and etanercept. Data represent means of 
urinary albumin/creatinine ratios ± SEM. (B) CpG-DNA treated Col4a3-deficient mice were injected with 
etanercept from week 4 to 6 of age as indicated. Survival time is illustrated as Kaplan-Meier curve.  
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5. Discussion 
 
Chronic renal failure involves progressive loss of renal parenchymal cells and fibrosis, 
which is accompanied by an infiltration of immune cells such as macrophages and T 
cells, followed by progressive glomerulosclerosis. A comprehensive understanding of 
the pathomechanisms of CKD still remains elusive. For example, the factors contributing 
to tissue damage and remodeling in the disease progression have not fully been defined 
yet. In the current study, we used Col4a3-deficient mice, which reflect the genetic and 
phenotypical characteristics of human Alport syndrome (Cosgrove et al., 1996) and, 
furthermore, represent a suitable model to study the pathomechanisms of the progressive 
glomerulosclerosis in absence of major inflammatory lesions. Studies using this model 
have demonstrated that renal cell activation and infiltrating leukocytes both contribute to 
the progression of renal dysfunction but little is known about how the renal cell 
activation and leukocytes promote tissue remodeling in Alport syndrome (Jedlicka et al., 
2009; Lebleu et al., 2008).  
 
The role of TNF-α in Alport nephropathy 
 
In the first study, we postulated that endogenous molecules, which are synthesized 
during the progression of Alport nephropathy, can enhance the progressive loss of renal 
cells. For example, the proapoptotic cytokine, TNF-α would contribute to Alport 
glomerulosclerosis by promoting podocyte loss.    
TNF-α is a multiple functional cytokine of proapoptotic and immunoregulatory 
functions. The biological function of TNF-α ligand arises via interaction with 
transmembranous receptors (TNFRs) comprising the recruited intracellular adaptor 
molecules such as FADD, RIP, TRADD, and TRAF. One pathway leads to induction of 
NF-kB-mediated cytokines that elicit proinflammatory or antiinflammatory effects via 
TNFR1 and TNFR2, whereas the TNFR1-binding pathway triggers an extrinsic 
apoptosis pathway by activating caspase 8 (Hehlgans and Pfeffer, 2005; Rahman and 
McFadden, 2006; Wajant et al., 2003). In kidney, TNFRs are expressed by  glomeruli 
and tubular cells in renal injury and, the increased expression and synthesis of TNF 
receptors and ligand indicate the evidence for glomerular pathology and it has been 
documented in a number of animal models of severe glomerular inflammation (Ortiz and 
Egido, 1995; Sanchez-Nino et al., 2010; Vielhauer and Mayadas, 2007). Here, we 
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confirmed that the expression of proinflammatory and proapoptotic cytokine TNF-α 
increased over time in glomerular and in tubulointerstitial compartments of Col4a3-
deficient mice. Data in this thesis also showed that leukocyte accumulation in kidneys 
from Col4a3-deficeint mice increased during the progression of Alport nephropathy and 
the leukocytes were also the source of TNF-α expression. The intrarenal TNF-α 
expressed by renal parenchymal cells and by infiltrating leukocytes promotes 
progressive glomerulosclerosis by enhancing podocyte loss. 
Loss-of-podocytes is the central pathophysiological element of glomerulosclerosis (Kriz 
and Lemley, 1999; Wharram et al., 2005). Podocytes are terminally differentiated 
epithelial cells and their sophisticated structural interaction with other podocytes via the 
slit membrane is elementary to their functional role at the glomerular filtration barrier. 
Hence, replacing a detached podocyte may be as difficult as replacing a single piece of a 
puzzle. Although intraglomerular podocyte progenitors have been reported, their 
capacity to regenerate dying podocytes in the adult kidney is limited (Appel et al., 2009; 
Ronconi et al., 2009). Therefore, in chronic forms of glomerulopathies with persistent 
triggers for podocyte injury, significant podocyte apoptosis is sufficient to cause diffuse 
glomerulosclerosis and decline of GFR (Kriz and Lemley, 1999; Wharram et al., 2005). 
In Alport nephropathy, the altered composition of the GBM affects podocytes, which is 
characterized by podocyte foot process effacement and proteinuria (Cosgrove et al., 
1996; Hudson et al., 2003).  
The immunohistological data from WT-1 and nephrin co-stained kidneys of Col4a3-
deficient mice indicate reliable quantification of the number of podocytes. Our finding is 
that the progression of glomerulosclerosis in Col4a3-deficient mice is tightly linked to 
the loss of nephrin-expressing differentiated podocytes like it has been reported for other 
forms of glomerulosclerosis (Kriz and Lemley, 1999; Sayyed et al., 2009; Susztak et al., 
2006; Wang et al., 2008; Wharram et al., 2005). Our hypothesis on the basis of the first 
study is that podocyte loss is enhanced by increasing intrarenal TNF-α expression and 
thus TNF-α blockade would reduce the glomerulosclerosis.  
TNF-α is a bifunctional cytokine. Its proinflammatory effects alert and activate other 
cells for cytokine production. This includes tissue macrophages that produce large 
amounts of reactive oxygen species upon TNF-α exposure as a dominant trigger for 
tissue inflammation and damage (Vielhauer and Mayadas, 2007). This fact is evidenced 
by genetic variants of increased TNF-α signaling, which lead to dwarfism, cachexia, and 
early death due to systemic and widespread tissue inflammation including the kidney 
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(Lee et al., 2000; Shembade et al., 2010). As such, TNF-α antagonism, e.g. with 
etanercept, has proven to be effective in genetic forms of inappropriate TNF-α signaling 
like TNF receptor–associated periodic syndrome (TRAPS) as well as in chronic 
inflammatory diseases such as rheumatoid arthritis or Crohn`s disease (Weinberg and 
Montler, 2005). In contrast to proinflammatory cytokines such as IL-6, TNF-α has 
profound proapoptotic effects as TNFRs activate the extrinsic apoptotic pathway 
involving caspase-8. As such, TNF-α expression in inflammatory lesions is thought to 
contribute to tissue damage by enhancing apoptotic cell death of intrinsinc parenchymal 
cells, e.g. tubular cell death in acute kidney injury (Choi et al., 2009; Dong et al., 2007). 
While apoptotic tubular cells can often rapidly be regenerated after acute kidney injury 
(Bonventre, 2003), persistent TNF-α expression may contribute to the progressive loss 
of renal parenchymal cells and tissue atrophy in CKD. TNF-α suppresses nephrin 
expression and induces podocyte apoptosis in a dose-dependent manner (Doublier et al., 
2010; Lai et al., 2009; Saito et al., 2010). We have demonstrated by TUNEL assays that 
the increased numbers of TUNEL-positive podocytes were observed in Col4a3-deficient 
mice. Furthermore, we document that TNF-α contributes to the progressive loss of 
podocytes in the glomerular compartment in vivo. This suggests that TNF-α at least 
partially accounts for progressive CKD and renal failure in Alport syndrome. In 
accordance with our hypothesis, the blockade of the biological activity of TNF-α with 
etanercept prolonged about 20% of total life span of Col4a3-deficient mice and the 
effect of etancercept was related to the improvement of all aspects of Alport nephropathy 
involving podocyte loss, proteinuria, glomerulosclerosis, and decline of GFR. This was 
evidenced by a partial restoration of nephrin-positive, differentiated podocytes in 
etanercept-treated Col4a3-deficient mice. Both mRNA and protein levels of nephrin 
were recovered and apoptotic podocytes were reduced by etanercept. TNF-α blockade 
with etanercept was previously shown to have similar protective effects on 
glomerulosclerosis of hypertensive rodents (Elmarakby et al., 2006), hence, TNF-α-
induced podocyte loss is likely to represent a general pathomechanism of 
glomerulosclerosis. 
  
The effect of macrophage-mediated TNF-α expression on Alport nephropathy 
 
In most types of acute and chronic kidney diseases it has been shown that leukocyte 
infiltrates contribute to disease progression by secreting proinflammatory and profibrotic 
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mediators (Boor et al., 2007; Eardley et al., 2008; Wilson et al., 2004). Experimental 
reduction of renal leukocytes, e.g. by irradiation, targeted deletion, specific toxins or by 
chemokine antagonism, was shown to protect from renal pathology and to improve the 
renal function (Anders et al., 2006; Ferenbach et al., 2007; Kitching et al., 2008; Sean 
Eardley and Cockwell, 2005). These findings are likely to extend to Alport nephropathy, 
because irradiation and blockade of chemokine receptor CCR1-mediated renal 
macrophage recruitment both proved to reduce renal fibrosis and prolonged life span in 
Col4a3-deficient mice (Katayama et al., 2008; Ninichuk et al., 2005).  
Persistent tissue injury results in recruitment of inflammatory immune cells and 
activation of non-immune cells including fibroblast and renal cells, which participate in 
inflammation and extracelluar matrix deposition by releasing a variety of 
proinflammatory and fibrogenetic products. Pathogen- or non-pathogen-derived innate 
immune responses trigger these processes, ultimately aggravating kidney disease. For 
example, a pathogen sensor TLR expressed by immune cells as well as by intrinsic renal 
cells can induce infiltration of inflammatory cells, cell activation, and fibrosis (Anders, 
2010; Schlondorff, 2008). Here, we first addressed the question whether renal fibroblasts 
were a major source of fibrogenetic products causing fibrosis in response to exogenous 
factors. Our data revealed that TLR-activated renal fibroblasts may be involved in 
inflammation but not in tissue remodeling. We showed that the expression of 
proinflammatory cytokines, e.g. IL-6 and CCL-2/MCP-1, was induced, while profibrotic 
molecules, e.g. collagen 1α, TGF-β, and smooth muscle actin, remained unchanged in 
the presence of TLR agonists. 
The precise role of intrarenal leukocytes with innate immunity in the pathology of Alport 
nephropathy however still remains unresolved. The blockade of the proinflammatory 
CC-chemokine CCL2/MCP-1 has no effect on kidney disease progression and survival 
of Col4a3-deficient mice (Clauss et al., 2009). This is suggesting as CCL2/MCP-1 
blockade or CCL2/MCP-1 deficiency prevents macrophage-mediated renal injury in 
multiple other models of chronic kidney disease (Vielhauer and Anders, 2009). We 
therefore postulated that CCL2/MCP-1 blockade fails to delay Alport nephropathy 
because chemokine receptor CCR2+ macrophages are relatively less in kidneys from 
Col4a3-deficient mice with non-inflammatory renal disease (Clauss et al., 2009). In fact, 
CCR2 is expressed by classically-activated (M1) macrophages that are readily recruited 
from the circulating monocytes into sites of intense inflammation (Mantovani et al., 
2004; Mosser and Edwards, 2008). However, the extent of tissue inflammation seems to 
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be rather low in Alport nephropathy. Hence, macrophages in Alport kidneys might 
display rather non-inflammatory phenotypes. For some tumors, and in late phases of 
wound healing, similar tissue macrophage phenotypes lacking CCR2 expression and 
displaying comparable functional properties, i.e. the alternatively-activated (M2) 
macrophages and immunoregulatory macrophages, have been reported (Gabrilovich and 
Nagaraj, 2009; Mantovani et al., 2005; Pollard, 2009; Varin and Gordon, 2009b). In fact, 
the phenotype or activation state of renal macrophages is thought to significantly affect 
the extent of renal inflammation and tissue damage (Ricardo et al., 2008). For example, 
ex vivo primed M1 or M2 macrophages maintain their phenotype after adoptive transfer 
into mice with adriamycin-induced glomerular sclerosis (Wang et al., 2007). 
Furthermore, M1 macrophage infusion aggravates renal damage and dysfunction, 
whereas M2 macrophage infusion reduces renal pathology and improves renal function. 
These studies are consistent with our previous findings that macrophage activation 
towards the M1 phenotype, e.g. with Met-RANTES or with bacterial DNA, aggravates 
immune complex glomerulonephritis (Anders et al., 2003a; Anders et al., 2003b).  
Here, we show that exposure to CpG-DNA, a synthetic mimic of bacterial DNA ligating 
TLR9, increased the number and activation state of intrarenal macrophages. This 
phenomenon was associated with a robust acceleration of renal disease progression. 
These data suggest first, that the natural course of Alport nephropathy involves a low 
degree of intrarenal inflammation associated with rather alternatively-activated 
macrophage infiltrates. Second, environmental stimuli like microbial DNA can drive 
disease progression by enhancing inflammation via modulating intrarenal macrophage 
numbers as well as their phenotype. Finally, TNF-α induction is a major element of 
CpG-DNA-induced acceleration of Alport nephropathy.  
The phenotypical diversity of tissue macrophages has evolved as a new research field 
but the classification of macrophage phenotypes still remains a matter of debate (Mosser 
and Edwards, 2008; Pollard, 2009; Varin and Gordon, 2009b). Classically-activated 
(M1) macrophages had been defined as an IL-12, IL-23, and MHCII expressing 
phenotype upon IFN-γ and TNF-α stimulation (Mantovani et al., 2004). By contrast, IL-
4 and/or IL-13 or IL-10 stimulation induce alternatively-activated (M2) macrophages 
that do not produce the aforementioned proinflammatory mediators but rather express 
IL-10, Arg-1, Fizz-1, and the mannose receptor (Mantovani et al., 2004). Alternatively-
activated macrophages seem to predominate in kidneys of Col4a3-deficient mice and 
may contribute to the remodeling of the extracellular matrix. For example, macrophage 
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metalloelastase was shown to contribute to the digestive damage of the GBM in Col4a3-
deficient mice (Rao et al., 2006b). By contrast, we found only very few CD11b+/Ly6Chi 
macrophages in kidneys of Col4a3-deficient mice at 6 weeks of age. This may explain 
why blocking the CC-chemokine CCL2/MCP-1 does not modulate murine Alport 
nephropathy (Clauss et al., 2009), although CCL2/MCP-1 blockade reduces the 
progression of most types of experimental kidney diseases by preventing the recruitment 
and activation of CCR2+ M1 macrophages (Mantovani et al., 2004; Ricardo et al., 
2008). Our data also demonstrate that systemic exposure to CpG-DNA is more potent 
than LPS to modulate intrarenal macrophages towards a proinflammatory phenotype as 
evidenced by increased numbers of CD11b+/Ly6Chi macrophages and renal mRNA 
expression of M1 macrophage markers in CpG-DNA-treated Col4a3-deficient mice. 
These results are consistent with the effects of CpG-DNA on cultured macrophages 
(Mantovani et al., 2005) and the effects of CpG-DNA injections in murine models of 
immune complex glomerulonephritis (Anders et al., 2003a; Anders et al., 2004). As a 
note of caution, such models involve effects of CpG-DNA on humoral immunity that 
may compromise conclusions on the role of glomerular macrophage phenotypes. A 
recent study has documented the role of activated macrophages in focal segmental 
glomerulosclerosis in further detail. Wang, et al. observed that the injection of ex vivo 
CpG-DNA-primed macrophages accelerated adriamycin nephropathy, while injection of 
resting macrophages had no effect (Wang et al., 2007). Our data are consistent with 
these results albeit we had injected CpG-DNA directly into the mice, thereby mimicking 
a environmental and systemic trigger of macrophage activation. Interestingly, CpG-DNA 
also induced M2 macrophage markers like Arg-1, TGF-β, mannose receptor, Fizz-1, and 
IL-10. Macrophage diversity is obviously more complex in tissue environments and is 
likely to extend beyond the M1/M2 paradigm (Mosser and Edwards, 2008). Irrespective 
of such classification issues, our data demonstrate that TNF-α induction is functionally 
crucial in CpG-DNA-accelerated Alport nephropathy. The TNF-α released by 
classically-activated macrophages accounts for inflammation and tissue damage in 
chronic rheumatic diseases, psoriasis, and Crohn`s disease. As shown in first study, the 
increased TNF-α expression by renal cells as well as infiltrated leukocytes was found in 
rather non-inflammatory type of Alport nephropathy. Furthermore, it has been 
demonstrated that TNF-α has a pivotal role of contributing to glomerulosclerosis by 
enhancing podocyte loss. Our key finding reported in the current study is that CpG-DNA 
switches macrophages towards the M1 phenotype. In turn, they increase renal TNF-α 
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expression and thus contribute to the acceleration of renal disease progression. 
Interestingly, our previous data reported in this thesis have shown that the TNF-α 
blockade with etanercept delayed glomerulosclerosis in Col4a3-deficient mice by 
reducing podocyte loss. This treatment also prevented the acceleration of Alport 
nephropathy and was consistent with the protective effect of TNF-α inhibitors in renal 
disease models that are associated with the presence of classically-activated 
macrophages (Choi et al., 2009; Elmarakby et al., 2006; Karkar et al., 2001; Lech et al., 
2009). In addition, macrophage-derived TNF-α mediates podocyte activation and 
dedifferentiation in vitro (Ikezumi et al., 2008). Taken together, our findings are that 
TNF-α expression in glomeruli promotes podocyte loss by CpG-DNA injection, and 
TNF-α blockade protects from CpG-DNA-induced acceleration of glomerulosclerosis. 
  
Our data in this thesis suggest that TNF-α plays a pivotal role in the pathogenesis of 
Alport nephropathy. Therefore, targeting TNF-α could be another novel potential 
therapy for AS. The TNF-α expression is increased by two possible ways: endogenous 
expression by renal intrinsic cells (podocytes) as well as infilatrated leukocytes during 
the progression of Alport nephropathy. It is also enhanced by M1 macrophage stimulated 
with environmental factors such as bacterial product (CpG-DNA). This represents that 
activation of TNF-α signaling accelerates podocyte loss contributing to 
glomerulosclerosis in Alport nephropathy (Figure 38). We show that TNF-α blockade 
with etanercept has beneficial effects in murine Alport nephropathy. Further studies in 
humans are demanded to confirm the beneficial effects in human AS. We conclude that, 
inhibition of the TNF-α signaling may be a novel potential therapeutic target to delay 
ESRD by reducing glomerulosclerosis in patients with Alport nephropathy.  
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Figure 38. The role of TNF-α on Alport kidney. TNF-α is expressed by both of renal intrinsic cells (e.g. 
podocytes) and by infiltrating leukocytes (e.g. macrophages). The secretion of TNF-α alone contributes to 
the Alport glomerulosclerosis by inducing podocyte loss and external signal (e.g. baterial CpG-DNA) 
induced-macrophage phenotype switch towards M1 macrophages remarkably increased TNF-α expression 
leading to the aggravation of glomerulosclerosis by podocyte loss.  
 
 
 
 
 
 
 
Glomerulus 
Podocyte loss 
TNF-α 
Bacterial product (e.g. CpG-DNA) 
Monocytes M2 macrophages 
M1 macrophages 
TNF-α 
Glomerulosclerosis 
Acceleration  
Differentiation/ 
Phenotype switch 
Damage-induced  
Endogenous factor 
Environmental factors 
   90 
6. Summary and conclusion 
The pathomechanisms of the progression of chronic kidney diseases involve progressive 
glomerulosclerosis with renal parenchymal cell loss by proapoptotic factors. Tumor 
necrosis factor-alpha (TNF-α) is a proapoptotic cytokine that is produced by 
macrophages as well as by a variety of cell types. TNF-α signaling regulates cell 
survival and death. Like in other inflammatory renal diseases, the increased intrarenal 
TNF-α expression contributes to the disease progression of Alport nephropathy, “a non-
inflammatory” murine CKD model. I show that TNF-α expressed by podocytes as well 
as by infiltrating leukocytes progressively activates renal parenchymal cells, inducing 
apoptotic pathways that can trigger glomerulosclerosis in Alport disease. The blockade 
of TNF-α by etanercept prolonged mean survival of Col4a3-deficient mice. The 
beneficial effect on life span was associated with a significant improvement of the 
glomerulosclerosis, proteinuria, and the glomerular filtration rate (GFR). In particular, 
etanercept treatment significantly increased the number of glomerular podocytes (WT-1 
and nephrin co-staining) and the renal mRNA expression of nephrin and podocin 
without affecting markers of renal inflammation. The increased number of podocytes 
was consistent with less TUNEL-positive podocytes that undergo apoptosis.  
Importantly, exogenous signals, e.g. infections or toxins, have the potential to regulate 
the influx of immune cells including dendritic cells, macrophages, neutrophils, and T 
cells. Here I report a large influx of leukocyte subsets that are mostly dendritic cells and 
macrophages in Col4a3-deficient mice as compared to wildtype mice. While bacterial 
endotoxin treatment had no effect on the renal disease progression, bacterial cytosine-
guanine (CpG)-DNA exacerbated all aspects of Alport nephropathy and reduced the 
overall life span of Col4a3-deficient mice. This effect of CpG-DNA was associated with 
a significant increase of renal CD11b+/Ly6Chigh macrophages, intrarenal production of 
TNF-α, iNOS, IL-12, and CXCL10. CpG-DNA switched intrarenal macrophages from 
non-activated phenotype (M2) towards the classically activated form (M1). These M1 
macrophages increased the secretion of TNF-α, which accelerated the disease 
progression of Alport nephropathy by inducing podocyte loss.  
Taken together, I demonstrated that TNF-α is a crucial cytokine which induces podocyte 
loss in the natural course of the progression of Alport nephropathy. Moreover, the 
expression of TNF-α is enhanced by selective exogenous factors, e.g. TLR9 activation, 
which alter the phenotype of renal macrophages towards the M1 phenotype. TNF-α 
blockade might therefore represent a novel therapeutical option to delay the progression 
of Alport nephropathy and potentially of other forms of glomerulosclerosis in non-
inflammatory and inflammatory conditions. 
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7. Zusammenfassung 
Die Pathogenese des chronischen Nierenversagens beinhaltet die progrediente 
Glomerulosklerose mit dem Verlust von Nierenparenchymzellen durch proapoptotische 
Faktoren. Tumor-Nekrose-Faktor-alpha (TNF-α) ist ein proapoptotisches Zytokin, das 
sowohl von Makrophagen als auch von einer Vielzahl anderer Zellen gebildet und 
freigesetzt wird. Der TNF-α Signalweg reguliert Zellüberleben und Zelltod. Wie in 
anderen inflammatorischen Nierenerkrankungen trägt die gesteigerte intrarenale TNF-α- 
Expression zum Fortschreiten der Alport-Nephropathie, einer "nicht-inflammatorischen" 
chronischen Nierenerkrankung, im Mausmodell bei. TNF-α, das in Podozyten und 
infiltrierenden Leukozyten experimiert wird, aktiviert Nierenparenchymzellen über 
apoptotische Signalwege, was zu Alport-Glomerulosklerose führen kann. In der 
vorliegenden Dissertation berichte ich, dass die Blockade von TNF-α durch Etanercept 
die Lebensdauer von Col4a3-defizienten Mäusen verlängerte. Dieser positive Effekt auf 
die Lebensspanne war mit einer signifikanten Verbesserung der Glomerulosklerose, der 
Proteinurie und der glomerulären Filtrationsrate (GFR) verbunden. Vor allem die 
Etanercept-Behandlung erhöhte signifikant die glomeruläre Podozytenzahl und die 
renale mRNA-Expression von Nephrin und Podocin, ohne jedoch Marker der renalen 
Inflammation zu beeinflussen. Die zunehmende Zahl der Podozyten war mit einer 
Abnahme apoptotischer Podozyten assoziiert. 
Desweiteren können exogene Stimuli, wie zum Beispiel Infektionen oder Toxine, die 
Rekrutierung von Immunzellen (dendritische Zellen, Makrophagen, Neutrophile, T-
Lymphozyten) modulieren. Im Vergleich zu Nieren von Wildtyp-Mäusen beobachtete 
ich eine vermehrte Infiltration von Leukozyten, größtenteils bestehend aus dendritischen 
Zellen und Makrophagen in Col4a3-defizienten Nieren. Während das bakterielle 
Endotoxin LPS keinen Effekt auf die Progression des Krankheitsgeschehens hatte, führte 
die Stimulation mit Cytosine-Guanin-reicher DNA (CpG-DNA) zu einer Aggravation in 
allen Aspekten der Alport-Nephropathie und insbesondere zu einer verkürzten 
Lebensdauer der Col4a3-defizienten Mäuse. Dieser Effekt der CpG-DNA-Stimulation 
war assoziiert mit einer signifikant erhöhten Anzahl von renalen CD11b+/Ly6Chigh-
Makrophagen sowie einer vermehrten intrarenalen Produktion von TNF-α, iNOS, IL-12 
und CXCL10. CpG-DNA vermittelte die Makrophagen-Differenzierung vom 
unaktivierten M2-Phänotyp zum klassisch-aktivierten M1-Phänotyp. Interessanterweise 
sezernieren diese M1-Makrophagen vermehrt TNF-α, was die Progression der Alport-
Nephropathie durch zusätzlichen Verlust von Podozyten beschleunigt. 
Zusammenfassend konnte ich zeigen, dass TNF-α ein entscheidendes Zytokin bei der 
Induktion des Podozytenverlustes in der Pathogenese der Alport-Nephropathie ist. 
Darüber hinaus wird die Expression von TNF-α durch einzelne exogene Stimuli wie z.B. 
TLR9-Aktivierung hochreguliert, was den Phänotyp der renalen Makrophagen in 
Richtung M1 verschiebt. Die TNF-α-Blockade könnte daher eine therapeutische Option 
im Rahmen der Behandlung der Alport-Nephropathie sowie anderer Formen der nicht-
inflammatorischen und inflammatorischen Glomerulosklerose darstellen. 
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9. Abbreviations 
 
 
ACE Angiotensin-converting enzyme 
ADAS Autosomal dominant alport syndrome 
ARAS Autosomal recessive alport syndrome 
ARB AT1-receptor blockade 
Arg-1 Arginase-1 
AP-1 Activator protein-1 
APC Allophyocyanin 
AS Alport syndrome 
AS Ankylosing spondylitis 
AT Angiotensin  
BUN Blood urea nitrogen  
CCL2    Chemokine C-C motif ligand 2 
CCR2    Chemokine C-C motif receptor 2 
CCR5 Chemokine C-C motif receptor 5 
CKD Chronic kidney disease 
CLRs C-type lectin receptors  
COL Collagen  
Cp Crossing point 
CpG Cytidine-phosphate-guanosine  
CSF-1 Colony stimulating factor-1 
DCs Dendritic cells 
DD Death domain 
DN Diabetic nephropathy 
Ds double-stranded 
DTR Diphtheria toxin receptor 
ER Endoplasmic reticulum 
ESRD End-stage renal disease 
FADD FAS-associated death domain 
FCS Fetal calf serum 
FITC Fluorescein Isothiocyanate 
FSGS Focal segmental glomerulosclerosis 
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GBM Glomerular basement membrane 
GFR Glomerular filtration rate 
GPI Glycosylphosphatidylinositol  
HBSS Hanks´balanced salt solution 
HSP Heat shock protein 
IBD Inflammatory bowel disease 
IFN-γ Interferon-γ 
IKK IκB kinase 
IL Interleukin 
IL-1RII IL-1receptor II 
IRAK IL-1R-associated kinase 
IRI Ischemia reperfusion injury 
KDIGO Kidney Disease: Improving Global Outcomes  
K/DOQI Kidney Disease Outcomes Quality Initiative 
LBP LPS binding protein  
LPS Lipopolysaccharides 
LRR Leucin-rich-repeat 
LT-α Lymphotoxin-α 
MAL MyD88 adaptor like   
MAPK Mitogen-activated protein (MAP) kinase 
MCD Minimal change disease 
MCP-1 Monocyte chemoattractant protein-1 
MDA-5 Melanoma differentiation-associated gene 5 
MDP Muramyl dipeptide 
MDSCs Myeloid-derived suppressor cells 
MEKK1  MAPK kinase-1 
MHCII Major histocompatibility complex classs II 
MET Mesenchymal-to-epithelial transition 
MINCLE Macrophage-inducible C-type lectin 
MMP Matrix metallopeptidase 
MMP Mitochondrial membrane potential 
MMP-12 Matrix metallopeptidase-12  
MN Membranous nephropathy 
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NF-κB Nuclear factor kappa B 
NIK NF-κB inducing kinase 
NK Natural killer  
 
NLRs 
 
Nucleotide-binding oligomerization domain containing  
(NOD)-like receptors 
NO Nitric oxide 
NOS Nitric oxide synthase 
ODNs Oligodeoxynucleotides 
PAMPs Pathogen-associated molecular patterns  
PAS Periodic acid-Schiff stain 
PBS Phosphate-buffered saline 
pDCs Plasmacytoid DCs 
PRRs Pattern-recognition receptors 
RA Rheumatoid arthritis   
RIP Receptor interacting protein 
RLRs Retinoic acid-inducible gene (RIG)-I-like receptors  
ROS Reactive oxygen species 
SARM Sterile-alpha and Armadillo motif-containing protein  
SLE Systemic lupus erythematosus 
Ss Single-stranded 
TAB1 TAK1-binding protein 1 
TACE TNF-alpha converting enzyme 
TAK1 TGF-β-activated kinase 1 
TAMs Tumour associated macrophages 
Th T helper 
TGF-β Transforming growth factor-β  
TICAM-1 TIR domain-containing adaptor molecule  
TIR Toll/IL-1R homology 
TRAM TRIF-related adaptor molecule 
TIRAP Toll-interleukin 1 receptor (TIR) domain containing 
adaptor protein 
TLRs Toll-like receptors  
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TNF-α Tumor necrosis factor-α 
TNF-R1 TNF-receptor 1 
TRADD TNFR-associated death domain 
TRAF TNF receptor associated factors 
TRAPS TNF receptor–associated periodic syndrome 
TRIF TIR-domain-containing adapter-inducing interferon-β 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
UACR Urinary albumin to creatinine ratio 
US United States 
UUO Unilateral ureteric obstruction 
XLAS X-linked alport syndrome 
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glomerulosclerosis by promoting podocytes loss. 
• May. 2011: Deutsche Gesellschaft für Innere Medizin (DGIM), Wiesbaden. 
Germany. Poster presentation 1: Tumor necrosis factor-α-drives Alport 
glomerulosclerosis by promoting podocytes loss. Poster presentation 2: An orally 
active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and 
renal failure in type 2 diabetes. 
• March. 2011: 23rd Annual Meeting of the European Renal cell study group, 
Lake Garda, Italy. Oral Presentation: Tumor necrosis factor-α-drives Alport 
glomerulosclerosis by promoting podocytes loss. 
• Nov. 2010: Renal week 2010, American Society of Nephrology, Denver, USA. 
Free communication invited. Bacterial CpG-DNA accelerates Alport 
glomerulosclerosis by inducing an M1 macrophage phenotype and tumor 
necrosis factor-α-mediated podocyte loss. 
• July. 2010: Fellows Night des Nephrologie-Forum. Munich, Germany. Oral 
Presentation. An orally active chemokine receptor CCR2 antagonist prevents 
glomerulosclerosis and renal failure in type 2 diabetes. 
• June. 2010:  European Renal Association (ERA-EDTA) 2010, Munich, 
Germany. Oral Presentation: Bacterial CpG-DNA accelerates Alport 
glomerulosclerosis by inducing an M1 macrophage phenotype and tumor 
necrosis factor-α-mediated podocyte loss. 
Poster: An orally active chemokine receptor CCR2 antagonist prevents 
glomerulosclerosis and renal failure in type 2 diabetes. 
• March. 2010: 22nd Annual Meeting of the European Renal cell study group, 
Wien, Austria. Oral Presentation: Bacterial CpG-DNA accelerates Alport 
glomerulosclerosis by inducing an M1 macrophage phenotype and tumor 
necrosis factor-α-mediated podocyte loss. 
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RESEARCH EXPERIENCES                                                     
Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, 
Charité-Universitätsmedizin Berlin. Berlin, Germany 
Masters thesis (Diplomarbeit). “Influence of Streptococcus pneumoniae (S.p) on the 
function of the glucocorticoid receptor pathway in pulmonary epithelial cells”. August 
2006 – April 2007. 
 
Department of Cellular Microbiology, Max-Planck Institute for Infection 
Biology. Berlin, Germany      
Study Project. “Development of the vector system to study the formation of neutrophil 
extracellular traps (NETs)”. July 2005 – November 2005. 
 
AWARDS                                                                  
• Academic scholarship, Technical University of Berlin (September 2004 – Decem
ber 2004) 
• Participation of scientists in joint projects under the agreement of scientific coope
ration granted by DFG (September 2004) 
• Academic scholarship of the German Academic Exchange Service (DAAD), Tec
hnical University of Berlin (October 2006 – August 2007)  
• Best abstract presented by young authors, European Renal Association (ERA-ED
TA) 2010 and 2011 
• Teaching/Research Assistantship, LMU, 2010 
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